[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10865
1. Bonneville JF, Cattin F, Bonneville F: [Imaging of pituitary adenomas]. Presse Med; 2009 Jan;38(1):84-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging of pituitary adenomas].
  • In pituitary adenomas with suprasellar extension, MRI shows the tumor's relation to the surrounding structures: the optic chiasm, the internal carotid artery, the sphenoidal sinus, etc.
  • MRI usually makes it possible confirm or rule out any cavernous sinus invasion by the pituitary adenoma, a determination essential for planning treatment.
  • After pituitary surgery, MR imaging is again essential for visualizing any residual tumor tissue and - if the MRI is carefully performed to be reproducible - for assessing its development over time.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging / methods. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Contrast Media. Female. Follow-Up Studies. Gadolinium. Hemorrhage / diagnosis. Humans. Hyperpituitarism / diagnosis. Image Enhancement / methods. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm, Residual / diagnosis. Patient Care Planning. Prolactinoma / diagnosis. Sex Factors. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990539.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


2. Hernández Sandemetrio R, Armengot Carceller M, Alba García JR, Taleb C, Jiménez Roig JP, Frías Moya-Angeler S, Basterra Alegría J: [Pleomorphic adenoma of deep lobe of the parotid gland]. Acta Otorrinolaringol Esp; 2006 Jan;57(1):56-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic adenoma of deep lobe of the parotid gland].
  • [Transliterated title] Adenoma pleomorfo gigante de lóbulo profundo de la parótida: a propósito de un caso.
  • This report describes a case of a pleomorphic adenoma in the deep lobe of the parotid gland presented like a parapharyngeal mass, and its diagnosis and treatment.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503035.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Yoshida A, Sen C, Asa SL, Rosenblum MK: Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol; 2008 Nov;32(11):1736-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation.
  • The patient was treated with thyroid radioablation and hormone replacement and followed for 7 years, during which time the tumor grew to 4.6 cm.
  • At transsphenoidal surgery, a tumor consisting of a pituitary adenoma and adamantinomatous craniopharyngiomalike components was resected.
  • Both components were closely intermingled, but there was no evidence of an intermediate morphologic phenotype.
  • Immunohistochemically, the adenoma was not only positive for beta-thyroid stimulating hormone, alpha subunit, and pituitary transcription factor 1, but also stained for beta-follicle stimulating hormone, steroidogenic factor-1, adrenocorticotropic hormone, and pituitary-restricted transcription factor (Tpit), exhibiting an unusual plurihormonal profile.
  • This lesion may represent an unusual composite tumor attributable to divergent differentiation of a common precursor.
  • Alternatively, it may be viewed as a pituitary adenoma showing metaplastic change analogous to the development of squamous cell nests of the pars tuberalis from adenohypophyseal endocrine cells.
  • [MeSH-major] Adenoma / pathology. Craniopharyngioma / pathology. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769335.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


Advertisement
4. Ulu EM, Uyuşur A, Ekici Y, Hunca C, Coşkun M: Multidetector CT findings of spontaneous rupture of hepatic adenoma in a patient with hepatic adenomatosis. Diagn Interv Radiol; 2009 Jun;15(2):135-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector CT findings of spontaneous rupture of hepatic adenoma in a patient with hepatic adenomatosis.
  • Hepatic adenomatosis (HA) is characterized by more than 10 adenomas in the liver, frequently scattered within both lobes.
  • We report the case of a 32-year-old woman who presented with a large intraparenchymal and subcapsular hematoma in the liver, and an underlying large adenoma with atypical radiologic characteristics detected with multidetector CT imaging.
  • On follow-up CT examination, a large adenoma was clearly visualized at the site of the previous hematoma.
  • [MeSH-major] Adenoma / diagnosis. Hematoma / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517384.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T: Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J; 2006 Feb;53(1):125-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
  • We reviewed the cases of 32 patients with growth hormone (GH)-secreting macroadenoma who underwent short-term octreotide treatment before transsphenoidal surgery to determine which types of adenoma the preoperative treatment were sensitive and whether predictors of tumor shrinkage could be identified.
  • The effects of preoperative octreotide treatment, endocrinologic effect and effect on tumor volume in 32 patients were evaluated retrospectively in relation to tumor features on magnetic resonance images and responses to endocrinologic challenge tests.
  • At a daily dose of 300 microg for 2-3 weeks, octreotide reduced serum GH and insulin-like growth factor-1 (IGF-1) levels to 31.9 % and 51.6% of pretreatment values, respectively, and led to a mean tumor volume of 68% of pretreatment volume in 52% of the patients.
  • The endocrinologic effect and the effect on tumor volume were larger in Knosp grades 0-2 than in Knosp grades 3-4.
  • Tumor shrinkage occurred significantly more often among patients that had a good response to both octreotide and bromocriptine challenge tests.
  • For surgical removal of the tumor, the effect of reducing tumor to 68% of pretreatment volume will be beneficial for the macroadenomas of Knosp grades 1-2.
  • Preoperative short-term octreotide treatment is effective for GH-secreting macroadeomas of Knosp grades 1-2 and a good response to both octreotide and bromocriptine challenge tests is a predictor of subsequent tumor shrinkage.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / pathology. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology
  • [MeSH-minor] Acromegaly / etiology. Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Predictive Value of Tests. Preoperative Care / methods. Time Factors. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543682.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


6. Rosenberg L, Boggs D, Wise LA, Palmer JR, Roltsch MH, Makambi KH, Adams-Campbell LL: A follow-up study of physical activity and incidence of colorectal polyps in African-American women. Cancer Epidemiol Biomarkers Prev; 2006 Aug;15(8):1438-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Physical activity is associated with a reduced risk of colon cancer, but the effect of activity on colorectal adenomas, which are precursors to colon cancer, is uncertain.
  • The influence of physical activity on colorectal adenomas among African-American women is of particular interest because African-American women have an increased risk of colon cancer relative to other U.S. women.
  • A review of medical records of 58 women who reported colorectal polyps indicated that 59% had adenomas and 41% had hyperplastic polyps.
  • The inverse association was apparent among most subgroups examined, including women who may be at higher risk of colorectal adenomas because of being obese.


7. Fushiki H, Morijiri M, Maruyama M, Motoshima H, Watanabe Y: MRI of intranasal pleomorphic adenoma. Acta Otolaryngol; 2006 Aug;126(8):889-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of intranasal pleomorphic adenoma.
  • A pleomorphic adenoma in the nasal cavity constitutes a rarity.
  • A 48-year-old woman presented with intranasal pleomorphic adenoma revealed by unilateral continuous obstruction and occasional epistaxis.
  • Unlike cases affecting the major salivary gland, magnetic resonance image (MRI) revealed that the mass showed a low signal intensity on T1-weighted image and a heterogeneous, intermediate signal intensity on T2-weighted image.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Magnetic Resonance Imaging. Nose Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16846937.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


8. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy.
  • PURPOSE: This study was designed to confirm the safety of not removing small adenoma in patients who undergo colorectal cancer surgery.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • Eighty-eight polyps were resected endoscopically, and histology showed neither cancer nor adenomas with high-grade dysplasia.
  • Two hundred fifty-five polyps detected in the same patient cohort during index/repeat colonoscopy were removed, including four adenomas with high-grade dysplasia and two T1 cancers.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Reoperation


9. Portocarrero-Ortiz L, Bonifacio-Delgadillo D, Sotomayor-González A, Garcia-Marquez A, Lopez-Serna R: A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors. Pituitary; 2010 Sep;13(3):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ACTH-secreting tumors represent 10% of functioning pituitary adenomas, and most of them are microadenomas.
  • Each of them had a confirmed diagnosis of Cushing disease and a negative dynamic MRI for microadenoma using full-dose gadopentetate dimeglumine.
  • All were recognized on the basis of the presence of a hypointense nodular lesion surrounded by normal contrast-enhanced tissue.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2010 Jun;72 (6):793-9 [19811509.001]
  • [Cites] Radiology. 2005 Dec;237(3):1014-9 [16237142.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] Neurochirurgie. 2002 May;48(2-3 Pt 2):149-62 [12058122.001]
  • [Cites] Radiology. 1990 Oct;177(1):35-8 [2399335.001]
  • [Cites] Radiographics. 1989 Jul;9(4):587-98 [2756189.001]
  • [Cites] Radiology. 1990 Aug;176(2):419-28 [2164234.001]
  • [Cites] Radiology. 1991 Sep;180(3):779-84 [1871293.001]
  • [Cites] Radiology. 1991 Feb;178(2):441-5 [1987606.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5134-40 [15941871.001]
  • [Cites] Eur J Endocrinol. 2000 Dec;143(6):761-8 [11124859.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):671-9 [8079866.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] Radiology. 1993 Oct;189(1):205-10 [8372195.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):196-203 [12519852.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):495-507 [18688636.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):241-8 [17287414.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):690-6 [10782779.001]
  • (PMID = 20182808.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


10. Uro-Coste E: [2009 update in salivary gland tumoral pathology]. Ann Pathol; 2009 Sep;29(4):274-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [2009 update in salivary gland tumoral pathology].
  • Histologic grade is a significant predictor of outcome in salivary gland carcinomas.
  • (ii) extracapsular invasion of carcinoma ex pleomorphic adenoma should be measured because it is now a known prognostic marker;.
  • (iii) the MIB-1 proliferative index is the most useful immunohistochemical marker for prognosis of all salivary gland carcinomas.
  • The PLAG1 and HMGA2 gene translocations have so far been identified only in pleomorphic adenomas, and their detection may potentially aid in diagnosis.
  • Newly recognized entities are summarized with special interest on differential diagnosis pitfalls: oncocytic mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, sclerosing polycystic adenosis, lymphadenoma, lipoadenoma, newly recognized morphological variants of epithelial-myoepithelial carcinoma, cribriform adenocarcinoma of the tongue, signet ring adenocarcinoma of minor salivary gland.
  • [MeSH-major] Salivary Gland Neoplasms / pathology


11. Galusca B, Dumollard JM, Lassandre S, Niveleau A, Prades JM, Estour B, Peoc'h M: Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch; 2005 Jul;447(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia.
  • Little is known about this epigenetic event in thyroid neoplasia.
  • 5-mc immunostaining scores were calculated in 17 papillary thyroid carcinomas (PTC), 6 follicular thyroid carcinomas (FTC), 16 follicular adenomas (FA), 19 nodular goiters (NG) and ten Hürthle cells adenomas (HCA).
  • Computerized image analysis showed a significant lower level of 5-mc immunostaining in thyroid carcinoma when compared with benign tumors or adjacent normal thyroid parenchyma (P<0.0001).
  • Overall, 5-mc accuracy to distinguish malign from benign thyroid tumors was similar to that of galectin-3 (89% versus 87%, P>0.05).
  • Among follicular neoplasia 5-mc accuracy to differentiate malign tumors trends to be higher than galectin-3 one (90% versus 66%, P=0.06).
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. DNA Methylation. Goiter, Nodular / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Epigenesis, Genetic. Galectin 3 / analysis. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Nov;47(5):689-93 [11034586.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):950; author reply 950-1 [12574240.001]
  • [Cites] Diagn Cytopathol. 1985 Apr-Jun;1(2):123-32 [3841772.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Biotech Histochem. 2000 Nov;75(6):251-8 [11131565.001]
  • [Cites] Diagn Cytopathol. 2002 Jun;26(6):366-72 [12112826.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4806-10 [12364477.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] Gut. 1996 Sep;39(3):434-8 [8949650.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):110-3 [14732779.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Pol J Pathol. 2003;54(2):111-5 [14575419.001]
  • [Cites] Cancer Lett. 2003 Sep 10;199(1):69-73 [12963125.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1117-23 [14614051.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Pathol Res Pract. 2003;199(6):399-404 [12924440.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1115-21 [15490053.001]
  • [Cites] Endocr Pract. 2004 Jan-Feb;10(1):31-9 [15251619.001]
  • [Cites] Thyroid. 2001 Dec;11(12 ):1147-51 [12186502.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2316-21 [12727856.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):212-6 [15256110.001]
  • [Cites] Rev Med Chil. 2003 Sep;131(9):965-72 [14635582.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):112-8 [9921982.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57 [10404820.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] Endocrine. 2003 Nov;22(2):81-4 [14665710.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1993-7 [15274390.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4792-6 [12364475.001]
  • [Cites] Biomed Pharmacother. 2004 Jul-Aug;58(6-7):356-9 [15271416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5152-8 [11701669.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1495-500 [15274315.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Oct;77(4):991-5 [7691865.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):183-8 [15252732.001]
  • [Cites] Hum Pathol. 2001 Aug;32(8):856-62 [11521231.001]
  • [Cites] Thyroid. 2003 Apr;13(4):381-7 [12804106.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):311-7 [15233548.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):479-84 [12964023.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Biochem J. 1994 Mar 15;298 Pt 3:537-41 [8141765.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2312-5 [12727855.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):427-32 [15489135.001]
  • (PMID = 15891902.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


12. Hüneburg R, Lammert F, Rabe C, Rahner N, Kahl P, Büttner R, Propping P, Sauerbruch T, Lamberti C: Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy; 2009 Apr;41(4):316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening.
  • As there is evidence for a higher incidence of flat adenomatous precursors and because an accelerated adenoma-carcinoma sequence has been postulated for these patients, early detection of these lesions is essential.
  • RESULTS: A total of 128 hyperplastic and 52 adenomatous lesions were detected.
  • At least one adenoma was detected in 15 % of patients by both standard and NBI colonoscopy compared with 28 % of patients by chromocolonoscopy.
  • CONCLUSION: According to this study, chromocolonoscopy detects significantly more hyperplastic and, in particular, adenomatous lesions than standard white light colonoscopy or NBI.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy / methods. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Mass Screening / methods. Precancerous Conditions / diagnosis


13. Nishioka H, Haraoka J: Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas. Acta Neuropathol; 2005 Jun;109(6):598-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas.
  • Exocytosis proteins play an important role in the secretory activities of anterior pituitary cells and adenoma cells.
  • An immunohistochemical study was conducted to elucidate the functional significance of these proteins in growth hormone (GH)-producing adenomas.
  • We studied 40 GH-producing adenomas, 10 prolactinomas, and 10 clinically nonfunctioning (NF) adenomas immunohistochemically with antibodies specific for Rab3B and SNAP-25, both of which are considered essential in secretory activities of the pituitary, and keratin 8 (clone CAM5.2).
  • The tumor volume (TV) was estimated with high-resolution magnetic resonance imaging.
  • Immunoreactivity for Rab3B, which was granular in the cytoplasm, varied in GH adenomas, but was negative in prolactinomas and NF adenomas.
  • Reactivity for SNAP-25, which was linear on the plasma membrane, varied in GH adenomas, and was intensely positive in prolactinomas, and negative in NF adenomas.
  • In GH adenomas, an increased percentage of adenoma cells with dot-like immunoreactivity for keratin 8 was associated with decreased reactivities for Rab3B (R=0.739, P<0.0001) and SNAP-25 (R=0.840, P<0.0001).
  • The immunoreactivities for Rab3B and SNAP-25 may reflect the number of secretory granules and exocytosis activity, respectively, in pituitary adenomas, including GH adenomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895198.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / SNAP25 protein, human; 0 / Synaptosomal-Associated Protein 25; EC 3.6.1.- / RAB3B protein, human; EC 3.6.5.2 / rab3 GTP-Binding Proteins
  •  go-up   go-down


14. Grigor'ev EG, Vladimirova AA, Raevskaia LIu, Chashkova EIu: [Colonic serrated adenoma and its clinical significance]. Klin Med (Mosk); 2009;87(6):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic serrated adenoma and its clinical significance].
  • Serrated adenoma as an immediate precursor of colorectal cancer is included in the WHO classification (2003).
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670718.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 50
  •  go-up   go-down


15. Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F: Microvessel density and area in pituitary microadenomas. Endocr Pathol; 2009;20(4):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results suggest that pituitary adenomas at early developmental stage are either avascular or significantly less vascular than normal pituitary tissue and that differences in vascularity of pituitary adenomas associated with the variables of sex, age, clinical presentation and immunohistochemical phenotype reported in the literature can evolve with tumor growth and possibly acquire statistical significance in large macroadenomas.
  • [MeSH-major] Adenoma / blood supply. Microvessels / pathology. Pituitary Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2008 May;23 (5):601-7 [18283645.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2890-6 [15181073.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Endocr Pathol. 1997 Autumn;8(3):189-193 [12114722.001]
  • [Cites] Microsc Res Tech. 2003 Jan 1;60(1):98-106 [12500266.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):94-101 [15558070.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):175-81 [17159250.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):217-21 [8764929.001]
  • [Cites] Am J Pathol. 1972 Apr;67(1):109-26 [5055626.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):329-33 [9578082.001]
  • [Cites] J Histochem Cytochem. 2006 Apr;54(4):385-95 [16234507.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] Int J Exp Pathol. 2007 Aug;88(4):271-7 [17696908.001]
  • [Cites] Oncol Res. 2000;12(4):203-8 [11341470.001]
  • [Cites] Histopathology. 2001 Sep;39(3):310-9 [11532042.001]
  • [Cites] Fertil Steril. 2002 Sep;78(3):581-6 [12215337.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Clin Neuropathol. 1990 Sep-Oct;9(5):251-3 [2272145.001]
  • [Cites] Hum Reprod. 2003 May;18(5):1088-93 [12721189.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):131-9 [15299199.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Neuropathology. 2009 Feb;29(1):40-4 [18673444.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):161-9 [17200351.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):753-8 [16645024.001]
  • (PMID = 19705298.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


16. Klopfleisch R, Gruber AD: Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Res Vet Sci; 2009 Aug;87(1):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To analyze their role in the malignant progression of canine mammary tumors expression levels of p27 and p21 and its major regulator p53 were compared in simple adenomas, adenocarcinomas of the mammary gland and lymph node metastases with normal mammary gland.
  • Laser microdissection of tissue samples and real-time PCR were used for quantification of mRNA expression levels. p21 was overexpressed in adenocarcinomas, whereas adenomas and metastases expressed p21 more heterogeneously.
  • In contrast, p27 expression was reduced in the adenocarcinomas but heterogeneously expressed in adenomas and metastases.
  • Taken together the results suggest that loss of p21 overexpression is associated with tumor metastasis while reduced cell cycle inhibition by p27 is associated with malignant progression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185891.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


17. Colson A, Brooke AM, Walker D, Besser GM, Chew SL, Grossman AB, Jenkins PJ, Drake WM, Monson JP: Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res; 2006;66(6):257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
  • BACKGROUND/AIMS: This study was designed to determine whether previous Cushing's disease (CD) or prolactinoma (PRL) could exert adverse effects additional to those of growth hormone (GH) deficiency as a consequence of variable degrees of prior hypogonadism or hypercatabolism.
  • We report the effects of 5 years GH treatment in 124 GH deficiency adults; 42 patients with non-functioning pituitary adenomas (NFPA), 43 with treated PRL and 39 with treated CD.
  • [MeSH-major] Adenoma / physiopathology. Adenoma / therapy. Blood Glucose / metabolism. Body Composition / drug effects. Bone Density / drug effects. Human Growth Hormone / deficiency. Human Growth Hormone / therapeutic use. Lipid Metabolism / drug effects. Pituitary ACTH Hypersecretion / physiopathology. Pituitary ACTH Hypersecretion / therapy. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prolactinoma / physiopathology. Prolactinoma / therapy


18. Wong MH, Dobbins TA, Tseung J, Tran N, Lee CS, O'Brien CJ, Clark J, Rose BR: Oestrogen receptor beta expression in pleomorphic adenomas of the parotid gland. J Clin Pathol; 2009 Sep;62(9):789-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen receptor beta expression in pleomorphic adenomas of the parotid gland.
  • AIMS: Pleomorphic adenomas of the salivary gland have gender and age distributions suggesting that oestrogen has a causal role.
  • However, oestrogen receptor (ER)alpha is expressed at low levels in normal salivary gland tissues and data from salivary gland tumours are conflicting.
  • There is preliminary evidence that the recently described ERbeta may be the major ER in salivary gland tissue.
  • The aim of this study was to determine the nature and extent of ERbeta expression in pleomorphic adenomas of the salivary gland.
  • METHODS: Pleomorphic adenomas and normal tissues of the parotid gland from 49 patients were tested for ERalpha and ERbeta expression by semiquantitative immunohistochemistry.
  • RESULTS: ERalpha and ERbeta expression was localised mainly to the nuclei of ductal cells in normal tissues and the epithelial components in pleomorphic adenomas.
  • ERbeta was expressed in almost twice as many normal tissues and pleomorphic adenomas as ERalpha.
  • CONCLUSIONS: This is thought to be the first study of ERbeta in pleomorphic adenomas of the salivary gland.
  • Findings support ERbeta as the major ER in salivary glands, and provide evidence that ERbeta may have a role in the development of pleomorphic adenomas of the salivary gland.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Estrogen Receptor beta / metabolism. Parotid Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Factors. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Parotid Gland / metabolism. Sex Factors

  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734474.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Neoplasm Proteins
  •  go-up   go-down


19. Chiou YS, Tsai ML, Wang YJ, Cheng AC, Lai WM, Badmaev V, Ho CT, Pan MH: Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J Agric Food Chem; 2010 Aug 11;58(15):8833-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reports the inhibitory effect of dietary administration of pterostilbene against the formation of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) preneoplastic lesions and adenomas in male ICR mice and delineates its possible molecular mechanisms.
  • It was found that the dietary administration of pterostilbene effectively reduced AOM-induced formation of ACF and adenomas and inhibited the transcriptional activation of iNOS and COX-2 mRNA and proteins in mouse colon stimulated by AOM.
  • [MeSH-minor] Animals. Azoxymethane / adverse effects. Disease Models, Animal. Humans. Male. Mice. Mice, Inbred ICR


20. Ding XW, Luo HS, Jin X, Yan JJ, Ai YW: Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol; 2007;24(3):345-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Eag1 for gasric cancer patients and cell lines as well as gastric adenoma was investigated by immunohistochemistry and reverse transcription polymerase chain reaction.
  • Eag1 protein and mRNA were negatively expressed in paired non-cancerous matched tissues and 5 cases of adenoma tissues.
  • [MeSH-major] Adenoma / metabolism. Ether-A-Go-Go Potassium Channels / metabolism. Gene Expression Regulation, Neoplastic. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cell Line, Tumor. Cell Proliferation. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / diagnosis. Male. Matched-Pair Analysis. Middle Aged. Neoplasm Metastasis / physiopathology. RNA, Messenger / analysis. Reference Values

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Oct 15;18(20):5540-7 [10523298.001]
  • [Cites] J Gen Physiol. 2004 Oct;124(4):301-17 [15365094.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13030-7 [16537547.001]
  • [Cites] Nature. 2006 Mar 23;440(7083):440-7 [16554803.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2850-2 [16783874.001]
  • [Cites] Pharmacol Rev. 2005 Dec;57(4):473-508 [16382104.001]
  • [Cites] J Membr Biol. 2002 Jul 15;188(2):137-49 [12172639.001]
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):1-9 [16473665.001]
  • [Cites] FEBS Lett. 1998 Aug 28;434(1-2):177-82 [9738473.001]
  • [Cites] J Membr Biol. 2005 Jun;205(3):115-24 [16362499.001]
  • [Cites] Mol Cancer. 2006 Oct 05;5:42 [17022811.001]
  • [Cites] J Membr Biol. 2001 Jul 1;182(1):1-15 [11426295.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3438-42 [8159766.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6996-7001 [15466192.001]
  • [Cites] Receptors Channels. 2001;7(5):345-56 [11697078.001]
  • [Cites] J Physiol. 1998 Apr 1;508 ( Pt 1):49-56 [9490815.001]
  • [Cites] J Membr Biol. 2005 Jun;205(3):175-84 [16362505.001]
  • (PMID = 17873312.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ether-A-Go-Go Potassium Channels; 0 / KCNH1 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


21. Mihashi H, Kawahara A, Kage M, Kojiro M, Nakashima T, Umeno H, Sakamoto K, Chiziwa H: Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors. Kurume Med J; 2006;53(1-2):23-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors.
  • We investigated 115 patients with salivary gland epithelial tumors who had undergone preoperative fine needle aspiration cytology (FNAC) of salivary glands and had been diagnosed by postoperative histopathological examination.
  • We compared the findings of preoperative FNAC with their histopathological types in salivary gland tumors, and discuss the results and problems.
  • The rates of agreement in the diagnosis of pleomorphic adenoma, Warthin tumor, and basal cell adenoma were 96%, 92.9%, and 55.5%, respectively.
  • We realized again not only that the diagnostic accuracy of preoperative FNAC for salivary gland tumors was high, but also that it was a safe, easy-to-perform, clinically very useful diagnostic procedure.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043392.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Uchiyama Y, Imazu H, Kakutani H, Hino S, Sumiyama K, Kuramochi A, Tsukinaga S, Matsunaga K, Nakayoshi T, Goda K, Saito S, Kaise M, Kawamuara M, Omar S, Tajiri H: New approach to diagnosing ampullary tumors by magnifying endoscopy combined with a narrow-band imaging system. J Gastroenterol; 2006 May;41(5):483-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated the ability of magnifying endoscopy with NBI (MENBI) to diagnose and differentiate between benign and malignant ampullary tumors.
  • All adenomas and adenocarcinomas had type II and/or type III surface structures, and patients whose ampulla had a type I surface structure had only inflammatory or hyperplastic changes.
  • In addition, abnormal vessels were seen only in adenocarcinomas and never in adenomas.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Aged. Biopsy. Female. Follow-Up Studies. Humans. Inflammation. Male. Microscopy, Video. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Dec;36(12):1094-8 [15578301.001]
  • [Cites] Endoscopy. 1997 Mar;29(3):182-7 [9201467.001]
  • [Cites] Hum Pathol. 1985 Sep;16(9):901-10 [4029945.001]
  • [Cites] Endoscopy. 1988 Aug;20 Suppl 1:211-7 [3049059.001]
  • [Cites] Scand J Gastroenterol. 2000 Apr;35(4):337-44 [10831254.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):171-5 [12631460.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):27-33 [10385718.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):254-6 [2406980.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Gastrointest Endosc. 1984 Jun;30(3):163-6 [6735092.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1750-3 [11813616.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):237-41 [9324129.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Am Surg. 1982 Apr;48(4):188-90 [7081830.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Gastrointest Endosc. 2001 Nov;54(5):609-20 [11677478.001]
  • [Cites] Lasers Surg Med. 1992;12(6):585-97 [1453859.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1080-4 [15578298.001]
  • [Cites] Ann Surg. 1987 Nov;206(5):572-7 [3314748.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):540-8 [9576571.001]
  • [Cites] Gastrointest Endosc. 1992 Nov-Dec;38(6):676-83 [1473669.001]
  • [Cites] Ann Surg. 1988 Mar;207(3):234-9 [3345110.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):188-99 [1727753.001]
  • [Cites] Ann Surg. 1975 May;181(5):534-40 [1130871.001]
  • (PMID = 16799891.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


24. Youssef AS, Agazzi S, van Loveren HR: Transcranial surgery for pituitary adenomas. Neurosurgery; 2005 Jul;57(1 Suppl):168-75; discussion 168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcranial surgery for pituitary adenomas.
  • The transcranial approach is effective when resection becomes necessary for a portion of a pituitary macroadenoma that is judged to be inaccessible from the transsphenoidal route because of isolation by a narrow waist at the diaphragma sellae, containment within the cavernous sinus lateral to the carotid artery, projection anteriorly onto the planum sphenoidale, or projection laterally into the middle fossa.
  • The application of a transcranial approach in these circumstances may still be mitigated by response to prolactin inhibition of prolactinomas, the frequent lack of necessity to remove asymptomatic nonsecretory adenomas from the cavernous sinus, and the lack of evidence that sustained chemical cures can be reliably achieved by removal of secretory adenomas (adrenocorticotropic hormone, growth hormone) from the cavernous sinus.
  • Cranial base surgical techniques have refined the surgical approach to pituitary adenomas but have had less effect on actual surgical indications than anticipated.
  • Because application of the transcranial approach to pituitary adenomas is and should be rare in clinical practice, it is useful to standardize the technique to a default mode with which the surgical team is most experienced and, therefore, most comfortable.
  • [MeSH-major] Adenoma / surgery. Craniotomy / methods. Microsurgery / methods. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987585.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


25. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M: Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg; 2008 Mar;108(3):525-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
  • OBJECT: Nonfunctioning pituitary adenomas (NFPAs) are benign tumors of the pituitary gland that typically cause visual and/or hormonal dysfunction.
  • Surgery is the treatment of choice, but patients remain at risk for tumor recurrence for several years afterwards.
  • The authors evaluate the early results of surgery and the long-term risk of tumor recurrence in patients with NFPAs.
  • Determinations of recurrence or growth of the residual tumor tissue during the follow-up period were based on neuroradiological criteria.
  • RESULTS: Residual tumor after surgery was detected in 173 patients (36.4%).
  • Multivariate analysis showed that invasion of the cavernous sinus, maximum tumor diameter, and absence of tumor apoplexy were associated with an unfavorable surgical outcome.
  • When tumor removal appeared complete, younger age at surgery was associated with a risk of tumor recurrence.
  • In patients with incomplete tumor removal, adjunctive postoperative radiotherapy had a marked protective effect against growth of residual tumor.
  • However, tumor can recur in patients after apparently complete surgical removal.
  • In patients with incomplete tumor removal, radiation therapy is the most effective adjuvant therapy for preventing residual tumor growth.
  • [MeSH-major] Adenoma / surgery. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Risk Assessment. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312100.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Yip L, Tublin ME, Falcone JA, Nordman CR, Stang MT, Ogilvie JB, Carty SE, Yim JH: The adrenal mass: correlation of histopathology with imaging. Ann Surg Oncol; 2010 Mar;17(3):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Computed tomography (CT) and magnetic resonance (MR) imaging can help diagnose benign adrenal adenomas, but prior studies rely on nonoperative follow-up as proof of a lesion's benign nature.
  • Imaging results were considered to signify benign adrenal adenoma if one or more of the following was present: Hounsfield units <10 on unenhanced CT, contrast-enhanced CT quantifying absolute contrast washout of >60% or relative contrast washout of >40%, or MR with chemical-shift imaging demonstrating loss of signal intensity on out-of-phase images.
  • RESULTS: The sensitivity and specificity of preoperative imaging in predicting benign adrenal adenoma were 57 and 94%, respectively.
  • Histopathology confirmed that all 66 adrenal masses with imaging characteristics suggesting benign adenoma were indeed benign lesions and included 61 benign adrenal adenomas and 5 benign nonadenomatous lesions (3 myelolipomas, 1 composite myelolipoma/adenoma, and 1 ganglioliponeuroma).
  • CONCLUSION: CT or MR characteristics predicted the presence of benign lesions with 100% specificity.
  • Every adrenal malignancy had CT or MR results that were inconsistent with benign adenoma (100% sensitivity).
  • To exclude malignancy, adrenal masses with non-benign imaging characteristics should be resected.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / radiography. Adrenocortical Adenoma / pathology. Adrenocortical Adenoma / radiography. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Prognosis. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960266.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Wada N, Yoshida A, Miyagi Y, Yamamoto T, Nakayama H, Suganuma N, Matsuzu K, Masudo K, Hirakawa S, Rino Y, Masuda M, Imada T: Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res; 2008 Jan-Feb;28(1A):139-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MSAC gene expressions have been reported to be associated with tumor cell proliferation or unfavorable cancer behavior.
  • MATERIALS AND METHODS: Expression levels of MSAC genes (hBUB1, hBUBR1, hBUB3 and hMAD2) were evaluated in 9 follicular thyroid adenomas (FAs), 9 follicular thyroid carcinomas (FTCs), 21 papillary thyroid carcinomas (PTCs), 5 anaplastic (undifferentiated) thyroid carcinomas (ATCs) and 3 adjacent normal thyroid tissues (NTs) by real-time quantitative RT-PCR.
  • Advanced DTCs were defined as carcinoma with aggressive nature such as extrathyroid extension, distant metastasis, recurrence or death from the disease.
  • RESULTS: MSAC gene expressions varied in different thyroid tumors and fell in the order of ATC, DTC (PTC and FTC), FA and NT Carcinomas had higher expression compared to adenoma or normal tissue. hBUB1, hBUBR1 and hMAD2 expressions in ATCs were significantly higher than those in DTCs (p<0.005).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383837.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


28. Eswaran SL, Sanders M, Bernadino KP, Ansari A, Lawrence C, Stefan A, Mattia A, Howell DA: Success and complications of endoscopic removal of giant duodenal and ampullary polyps: a comparative series. Gastrointest Endosc; 2006 Dec;64(6):925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Increasing reports suggest that endoscopic removal of benign ampullary and duodenal polyps is safe and frequently definitive; however, most reported polyps have been small in size (<3 cm).
  • INTERVENTIONS: Endoscopic removal of duodenal and ampullary adenomas.
  • RESULTS: The outcomes of small and large adenoma removal include mean number of endoscopic retrograde cholangiopancreatographies required for complete removal (2.09 vs 2.56, P = .392), number of complications (4.5% vs 13.9%, P = .375), discovery of unsuspected cancer (0% vs 10.3%, P = .242), and final definitive resolution (100% vs 86.2%, P = .124).

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140900.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E: Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe. J S Afr Vet Assoc; 2005 Jun;76(2):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 10 most common tumours, comprising 73.7% of all cutaneous neoplasms, were mast cell tumours, squamous cell carcinomas, perianal gland adenomas, lymphomas, benign melanomas, haemangiosarcomas, sebaceous gland adenomas, fibrosarcomas, lipomas and malignant melanomas.
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adenoma / veterinary. Age Factors. Animals. Dogs. Female. Lipoma / epidemiology. Lipoma / pathology. Lipoma / veterinary. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / veterinary. Prevalence. Risk Factors. Sarcoma / epidemiology. Sarcoma / pathology. Sarcoma / veterinary. Sex Factors. Zimbabwe / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108522.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


30. Poloz TL, Shkurupiy VA: Potentialities of differential immunohistochemical diagnosis of some follicular tumors of the thyroid gland. Bull Exp Biol Med; 2008 Dec;146(6):794-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potentialities of differential immunohistochemical diagnosis of some follicular tumors of the thyroid gland.
  • Differential diagnosis of thyroid follicular adenomas, follicular cancer, and papillary cancer with follicular structure was carried out.
  • Proliferation coefficients, probability of atypia, and tumor growth activity were evaluated on the basis of quantitative proportions of proliferation and apoptosis genes expression, derived from indexes of labeled nuclei expressing Ki-67, bcl2, p53 and cytoplasm with expression of bcl2, p53 in cells of these tumors.
  • [MeSH-major] Immunohistochemistry / methods. Thyroid Gland / metabolism. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Humans. Ki-67 Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513386.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng; rus
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


31. Tabuenca Dopico O, Gutiérrez Mendiguchía C, Rego Iraeta A: [Incidental diagnosis of lymph node tuberculosis in an 111-indium-octreotide scintigraphy during a study of acromegaly]. Rev Esp Med Nucl; 2006 May-Jun;25(3):193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with clinical suspicion of acromegaly and no radiologic visualization of pituitary adenoma is presented. (111)In-DTPAOC scintigraphy was performed in order to localize an ectopic foci of GH production.
  • This case illustrate that (111)In-DTPAOC can be positive not only in tumoral but in benign pathology and, in specific cases, it can be a marker of inflammatory activity and useful for treatment monitoring.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / secretion. Aged. False Negative Reactions. Humans. Incidental Findings. Insulin-Like Growth Factor I / analysis. Male. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762275.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 142694-57-3 / SDZ 215-811; 67763-96-6 / Insulin-Like Growth Factor I; 7A314HQM0I / Pentetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down


32. Lozoya-González D, Farca-Belsaguy A, Peláez-Luna M, Vázquez-Ballesteros E, González-Galeote E, Salceda-Otero JC: [Endoscopic resection of ampullary adenoma.]. Rev Gastroenterol Mex; 2010;75(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic resection of ampullary adenoma.].
  • [Transliterated title] Resección endoscópica de adenoma del ámpula de Vater.
  • Ampullary adenomas can occur sporadically or as part of familial adenomatous polyposis syndrome.
  • Recurrence of adenomatous lesions treated endoscopically is 30%.
  • We present the case of a patient with an ampulla of Vater s adenoma successfully resected endoscopically previous assessment of the lesion by endoscopic ultrasound.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Endoscopy, Digestive System

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423788.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


33. Schmidt M, Thoma N, Dietlein M, Moka D, Eschner W, Faust M, Schröder W, von Hülst-Schlabrendorff M, Ehses W, Schicha H: 99mTc-MIBI SPECT in primary hyperparathyroidism. Influence of concomitant vitamin D deficiency for visualization of parathyroid adenomas. Nuklearmedizin; 2008;47(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-MIBI SPECT in primary hyperparathyroidism. Influence of concomitant vitamin D deficiency for visualization of parathyroid adenomas.
  • AIM of the study was to analyse the influence of a concomitant vitamin D deficiency on the results of (99m)Tc-MIBI studies in patients (pts) with primary hyperparathyroidism (pHPT).
  • Results of a dual-phase (99m)Tc-MIBI protocol with SPECT were compared with histopathology.
  • In pts with vitamin D deficiency the sensitivity of a (99m)Tc-MIBI SPECT study was lower than in those with normal vitamin D status (72% vs. 91%) and dependent on the value for PTH.
  • CONCLUSION: The likelihood of a pathological (99m)Tc-MIBI study being obtained in pts with pHPT is dependent on the parathyroid hormone level.
  • However, a negative influence of a low vitamin D level on the scintigraphic detection rate of a parathyroid adenoma could not be proven which may be due to the low number of pts with vitamin D deficiency.
  • [MeSH-major] Adenoma / radionuclide imaging. Hyperparathyroidism / radionuclide imaging. Parathyroid Neoplasms / radionuclide imaging. Technetium Tc 99m Sestamibi. Vitamin D Deficiency / radionuclide imaging

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278205.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


34. Hisamuddin IM, Wehbi MA, Schmotzer B, Easley KA, Hylind LM, Giardiello FM, Yang VW: Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev; 2005 Oct;14(10):2366-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
  • Sulindac is a nonsteroidal antiinflammatory drug with a chemopreventive effect in patients with familial adenomatous polyposis (FAP).
  • We recently showed that certain polymorphic forms of FMO3 with reduced activity were associated with a more favorable response to sulindac in preventing the formation of adenomas in patients with FAP without polyps at baseline.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 1999 Oct;66(4):431-8 [10546928.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):457-60 [15770010.001]
  • [Cites] Biochem Pharmacol. 2000 Jul 1;60(1):7-17 [10807940.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1960-8 [10874065.001]
  • [Cites] Curr Gastroenterol Rep. 1999 Oct;1(5):441-8 [10980984.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Drug Metab Dispos. 2002 Oct;30(10):1043-52 [12228178.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:124-37 [12795052.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):209-13 [12938085.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1005-10 [14651971.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6):885-94 [14652558.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):425-31 [14762779.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] Drug Discov Today. 2004 Jul 1;9(13):574-81 [15203093.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):12-21 [15252926.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:759-89 [15338773.001]
  • [Cites] J Pharmacol Exp Ther. 1977 Apr;201(1):8-13 [850147.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1993;33:179-99 [8494339.001]
  • [Cites] Cancer Detect Prev. 1994;18(4):253-8 [7982235.001]
  • [Cites] Eur J Biochem. 1996 Feb 1;235(3):683-9 [8654418.001]
  • [Cites] Gut. 1996 Apr;38(4):578-81 [8707091.001]
  • [Cites] Dig Dis Sci. 1998 Feb;43(2):311-6 [9512123.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1387-94 [9834266.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8357-62 [15623613.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2000 Jan;60(1-3):83-96 [10680778.001]
  • (PMID = 16214918.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052230; United States / NIDDK NIH HHS / DK / DK064399-05; United States / NCI NIH HHS / CA / R01 CA084197-09; United States / NIDDK NIH HHS / DK / R24 DK064399-05; United States / NCI NIH HHS / CA / CA084197-09; United States / NIDDK NIH HHS / DK / DK64399; United States / NIDDK NIH HHS / DK / R01 DK052230-11; United States / NCI NIH HHS / CA / R01 CA084197; United States / NIDDK NIH HHS / DK / R24 DK064399; United States / NCI NIH HHS / CA / R01 CA084197-07; United States / NCI NIH HHS / CA / CA53801; United States / NCI NIH HHS / CA / CA084197-07; United States / NIDDK NIH HHS / DK / DK052230-11; United States / NCI NIH HHS / CA / CA84197
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac; EC 1.13.- / Oxygenases; EC 1.14.13.8 / dimethylaniline monooxygenase (N-oxide forming)
  • [Other-IDs] NLM/ NIHMS37180; NLM/ PMC2213626
  •  go-up   go-down


35. Martinez C, Bhattacharya S, Freeman T, Churchman M, Ilyas M: Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes. J Pathol; 2005 May;206(1):100-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes.
  • This causes altered expression of a number of genes which provides the mechanistic basis of neoplastic change in normal epithelium.
  • In order to identify these genes, expression profiles of normal intestinal mucosa and intestinal adenomas from multiple intestinal neoplasia (Min) mice were compared.
  • A total of 116 genes were found to show significant changes in expression in adenomas compared with normal mucosa.
  • Furthermore, the inferred role of Mmps at the adenomatous stage of tumourigenesis suggests that this may represent the optimal therapeutic window for the use of Mmp antagonists as anti-cancer agents.
  • [MeSH-major] Adenoma / genetics. Gene Expression Regulation, Neoplastic. Intestinal Neoplasms / genetics. Matrix Metalloproteinases / genetics. Neoplasms, Multiple Primary / genetics
  • [MeSH-minor] Animals. Collagenases / genetics. Gene Expression. Gene Expression Profiling. Intestinal Mucosa / metabolism. Matrix Metalloproteinase 10. Matrix Metalloproteinase 13. Matrix Metalloproteinase 14. Matrix Metalloproteinases, Membrane-Associated. Metalloendopeptidases / genetics. Mice. Mice, Mutant Strains. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Pathological Society of Great Britain and Ireland
  • (PMID = 15809971.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mmp14 protein, mouse; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.- / Mmp13 protein, mouse; EC 3.4.24.- / Mmp17 protein, mouse; EC 3.4.24.22 / Matrix Metalloproteinase 10; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


36. Nouraei SA, Hope KL, Kelly CG, McLean NR, Soames JV: Carcinoma ex benign pleomorphic adenoma of the parotid gland. Plast Reconstr Surg; 2005 Oct;116(5):1206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex benign pleomorphic adenoma of the parotid gland.
  • BACKGROUND: Carcinoma in pleomorphic salivary adenoma is a common histologic subtype of primary parotid malignancy.
  • METHODS: In this study, 28 patients (predominantly male) with histologically diagnosed carcinoma in pleomorphic salivary adenoma presenting over 10 years were retrospectively reviewed.
  • RESULTS: Only 25 percent of patients had a previously treated pleomorphic salivary adenoma.
  • Although the presenting features suggested malignancy in some cases, overall they were nonspecific, overlapping with the presentation of benign disease.
  • The facial nerve was resected en bloc with the tumor in nine cases and immediately reconstructed with good reanimation results in patients with recent-onset facial paresis.
  • Only 44 percent of patients had a complete histologic tumor clearance, and this was the most significant determinant of survival (p < 0.01, log-rank analysis).
  • The locoregional control rate was 66 percent at 5 years, but recurrent disease proved invariably fatal.
  • Five-year disease-specific survival was 44 percent with a high rate of disease-specific mortality (87 percent).
  • CONCLUSIONS: Carcinoma in pleomorphic salivary adenoma is very difficult to diagnose preoperatively.
  • Fine needle aspiration cytology had a disappointingly low sensitivity for this tumor, potentially misdirecting surgical management.
  • While good locoregional disease control could be achieved with surgery and radiotherapy, carcinoma in pleomorphic salivary adenoma was shown to be aggressive with a high disease-specific rate of mortality.
  • Given that incomplete tumor resection was the most important prognostic factor, a high index of clinical suspicion, radical ablative surgery, and immediate soft-tissue and nerve reconstruction for proven cases are advocated.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Dose Fractionation. England / epidemiology. Facial Nerve / surgery. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217459.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Sanz C, Vezzosi D, Pigny P, Bennet A, Caron P: Multiple endocrine neoplasia type 2a and germ line C634G RET mutation diagnosed in an 80-year-old patient. Ann Endocrinol (Paris); 2009 Apr;70(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia type 2a and germ line C634G RET mutation diagnosed in an 80-year-old patient.
  • Neck ultrasonography and Tc-MIBI scintigraphy revealed a right parathyroid adenoma and a multinodular goiter.
  • On histopathologic examination, both thyroid lobes presented 13 foci of MTC without lymph node metastasis and the parathyroid gland presented a benign adenoma without hyperplasia.
  • [MeSH-major] Germ-Line Mutation / genetics. Multiple Endocrine Neoplasia Type 2a / genetics. Proto-Oncogene Proteins c-ret / genetics
  • [MeSH-minor] Adenoma / radionuclide imaging. Adrenalectomy. Aged, 80 and over. Calcitonin / blood. Catecholamines / urine. Goiter, Nodular / ultrasonography. Humans. Male. Parathyroid Neoplasms / radionuclide imaging. Parathyroidectomy. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroid Gland / radionuclide imaging. Thyrotropin / blood

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 2A.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201392.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Radiopharmaceuticals; 9002-71-5 / Thyrotropin; 9007-12-9 / Calcitonin; 971Z4W1S09 / Technetium Tc 99m Sestamibi; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  •  go-up   go-down


38. Roberts SS, Mendonça-Torres MC, Jensen K, Francis GL, Vasko V: GABA receptor expression in benign and malignant thyroid tumors. Pathol Oncol Res; 2009 Dec;15(4):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GABA receptor expression in benign and malignant thyroid tumors.
  • We examined the expression patterns of the GABAergic system in 70 human thyroid tumor samples (13 follicular adenomas, 14 follicular carcinomas, 43 papillary carcinomas) and adjacent normal thyroid by immunohistochemistry.
  • GABAA alpha2 was detected in metastatic-derived but not in primary-tumor derived cell lines.
  • Expression levels of GABAB R2 and GABA receptor associated protein (GABARAP) are increased in adenomas and thyroid cancer suggesting their role in early stages of thyroid tumorigenesis.
  • [MeSH-major] Receptors, GABA / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. Microtubule-Associated Proteins / metabolism. Receptors, GABA-A / metabolism. Receptors, GABA-B / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2006 Jul;144(3):332-44 [16527506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2803-8 [17296934.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):383-90 [11144533.001]
  • [Cites] Psychoneuroendocrinology. 1987;12(1):53-9 [2884685.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):69-80 [18221027.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):61-6 [7279009.001]
  • [Cites] Endocr Dev. 2007;10:140-72 [17684395.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Cell Tissue Res. 1981;220(4):873-9 [7296659.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2270-82 [11948410.001]
  • [Cites] Life Sci. 1990;46(21):1489-501 [2162457.001]
  • [Cites] Annu Rev Neurosci. 1994;17:569-602 [7516126.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51841-50 [14530254.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):27-30 [11121859.001]
  • [Cites] Prog Exp Tumor Res. 2007;39:91-8 [17314503.001]
  • [Cites] Med Hypotheses. 2006;67(1):33-5 [16516401.001]
  • [Cites] Thyroidology. 1989 Dec;1(3):105-8 [2484871.001]
  • [Cites] J Physiol Pharmacol. 1998 Jun;49(2):303-10 [9670113.001]
  • [Cites] Neuroscience. 1996 Aug;73(3):705-13 [8809792.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):414-24 [2380337.001]
  • [Cites] Med Sci Monit. 2001 May-Jun;7(3):377-81 [11386012.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Jun;18(2):247-53 [10464715.001]
  • [Cites] Neurosci Res. 1999 Nov;35(2):145-53 [10616918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2503-18 [15325588.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3017-24 [16303767.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):97-116 [15027888.001]
  • (PMID = 19381877.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GABARAP protein, human; 0 / Microtubule-Associated Proteins; 0 / Receptors, GABA; 0 / Receptors, GABA-A; 0 / Receptors, GABA-B
  •  go-up   go-down


39. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N: The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res; 2006 Jun;4(2):130-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging role of pituitary tumor transforming gene in tumorigenesis.
  • Pituitary tumor transforming gene (PTTG) is a newly discovered oncogene, and serves as a marker of malignancy grades in several forms of cancer, particularly endocrine malignancies such as pituitary adenomas.
  • In addition, 90% of pituitary adenomas overexpress PTTG, qualifying it as the best available marker for this disease.
  • Various growth factors, nuclear factors and hormones regulate PTTG expression in different tumor cells, which could be important to understand in order to obtain insight into the tumorigenic and tumor progression process.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):187-95 [8550832.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3715-23 [15769981.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):273-80 [15947102.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4341-9 [15886233.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Gene. 1999 Nov 29;240(2):317-24 [10580151.001]
  • [Cites] Lancet. 2000 Feb 26;355(9205):716-9 [10703804.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Science. 2000 May 26;288(5470):1379-85 [10827941.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19422-7 [10781616.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8484-91 [11115508.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):328-41 [11414475.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):5025-32 [11600580.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):277-83 [11805140.001]
  • [Cites] Mol Cell. 2002 May;9(5):931-43 [12049731.001]
  • [Cites] Science. 2002 Jul 26;297(5581):559-65 [12142526.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jun 15;102(1-2):73-82 [12191496.001]
  • [Cites] Genes Dev. 2002 Sep 1;16(17):2179-206 [12208841.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):233-7 [12324572.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8173-7 [12444553.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):462-70 [12403781.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):141-50 [12580928.001]
  • [Cites] Eur J Endocrinol. 2003 Feb;148(2):203-11 [12590639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Mol Endocrinol. 2003 Apr;17(4):600-9 [12554778.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2341-7 [12727994.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1381-8 [12727930.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jun;58(6):673-82 [12780741.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1631-9 [12958169.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5188-93 [12970167.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3775-82 [14666677.001]
  • [Cites] Endocr J. 2003 Dec;50(6):771-81 [14709851.001]
  • [Cites] Breast. 2004 Feb;13(1):80-1 [14759723.001]
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):481-3 [14966902.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):206-28 [9101137.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):85-8 [9202270.001]
  • [Cites] N Engl J Med. 1997 Sep 25;337(13):928-30 [9302310.001]
  • [Cites] Science. 1998 Feb 20;279(5354):1219-22 [9469815.001]
  • [Cites] Endocr J. 1998 Feb;45(1):35-43 [9625444.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2187-93 [9811450.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] J Endocrinol. 1999 Aug;162(2):163-6 [10425453.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(7):729-36 [10481784.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):891-8 [15514942.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(1):35-70 [15697170.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 27;331(1):86-92 [15845362.001]
  • [Cites] Mol Cancer. 2004 Jul 8;3:18 [15242522.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4222-31 [15178645.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):927-30 [2601824.001]
  • [Cites] Mol Endocrinol. 1991 Nov;5(11):1687-95 [1779971.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1182-7 [8098714.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1021-7 [8134105.001]
  • (PMID = 16809406.001).
  • [ISSN] 1539-4182
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR-02215
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Number-of-references] 66
  • [Other-IDs] NLM/ PMC1483889
  •  go-up   go-down


40. Esaki M, Matsumoto T, Yao S, Nakamura S, Hirahashi M, Yao T, Iida M: Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics. Hum Pathol; 2005 Jan;36(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics.
  • The duodenum is the second most frequent site of cancer in patients with familial adenomatous polyposis (FAP).
  • The main objective of this study was to evaluate the cell kinetics in duodenal and ampullary adenomas in FAP.
  • The endoscopic and biopsy findings of duodenal adenomas in 22 FAP subjects and 18 non-FAP subjects were compared.
  • Adenomas in FAP included 15 ampullary adenomas and 17 nonampullary adenomas.
  • All 50 adenomas were histologically verified to be tubular adenoma with low-grade dysplasia.
  • In patients with FAP, duodenal adenoma tended to have a higher Ki-67-labeling index than the ampullary adenoma (54.3 +/- 11.3 versus 46.8 +/- 12.7; .05 < P < .1).
  • In addition, the Ki-67-labeling index in endoscopically normal or slightly enlarged ampullary adenoma was significantly higher than that in markedly enlarged ampullary adenoma (51.8 +/- 11.4 versus 39.4 +/- 11.3; P < .05).
  • Duodenal adenoma in FAP subjects was not found to have a higher proliferative activity or a smaller degree of apoptosis compared with those in non-FAP subjects.
  • The smaller proliferative activity in larger ampullary adenoma may thus be related to the static nature of ampullary adenoma in FAP.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyposis Coli / complications. Apoptosis / physiology. Duodenal Neoplasms / metabolism. Duodenal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Cell Proliferation. Common Bile Duct Neoplasms / metabolism. Common Bile Duct Neoplasms / pathology. Cyclooxygenase 2. Female. Genes, APC. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Male. Membrane Proteins. Middle Aged. Mutation. Polymorphism, Single-Stranded Conformational. Prostaglandin-Endoperoxide Synthases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712184.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


41. Gay F, Estornes Y, Saurin JC, Joly-Pharaboz MO, Friederich E, Scoazec JY, Abello J: In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol; 2008 Oct;39(10):1420-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma.
  • Moreover, gelsolin protein was down-regulated in a large proportion of high-grade adenomas (14/16) before the acquisition of invasive properties but in only a small proportion of low grade adenomas and serrated adenomas (2/30) and in none of the 9 cases of nonneoplastic hyperplastic polyps tested.
  • Our results therefore demonstrate that gelsolin down-regulation is an early and almost constant event in colon carcinogenesis and is associated with the transition from adenoma to carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / metabolism. Colonic Neoplasms / metabolism. Gelsolin / metabolism
  • [MeSH-minor] Aged. Cell Count. Colectomy. Colon / anatomy & histology. Colon / metabolism. Down-Regulation. Female. Humans. Immunoenzyme Techniques. Intestinal Mucosa / cytology. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Microsatellite Repeats. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656242.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gelsolin; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


42. Poole EM, Hsu L, Xiao L, Kulmacz RJ, Carlson CS, Rabinovitch PS, Makar KW, Potter JD, Ulrich CM: Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2010 Feb;19(2):547-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.
  • BACKGROUND: Prostaglandins are important inflammatory mediators; prostaglandin E2 (PGE2) is the predominant prostaglandin in colorectal neoplasia and affects colorectal carcinogenesis.
  • Prostaglandins are metabolites of omega-6 and omega-3 polyunsaturated fatty acids; their biosynthesis is the primary target of nonsteroidal anti-inflammatory drugs (NSAID), which reduce colorectal neoplasia risk.
  • METHODS: We investigated candidate and tagSNPs in PGE2 synthase (PGES), PGE2 receptors (EP2 and EP4), and prostaglandin dehydrogenase (PGDH) in a case-control study of adenomas (n = 483) versus polyp-free controls (n = 582) and examined interactions with NSAID use or fish intake, a source of omega-3 fatty acids.
  • RESULTS: A 30% adenoma risk reduction was observed for EP2 4950G>A (intron 1; OR(GA/AA vs. GG), 0.71; 95% confidence interval, 0.52-0.99).
  • For the candidate polymorphism EP4 Val294Ile, increasing fish intake was associated with increased adenoma risk among those with variant genotypes, but not among those with the Val/Val genotype (P(interaction) = 0.02).
  • CONCLUSIONS: These data provide little support for associations between adenoma risk and genetic variability related to PGE(2), yet suggest gene-environment interactions with anti-inflammatory exposures.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):163-73 [18038187.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2007 Jul;77(1):15-20 [17644362.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):813-30 [7634976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):659-68 [10744125.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3566-9 [11325819.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3971-6 [11751489.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Genet Epidemiol. 2001;21 Suppl 1:S626-31 [11793751.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] J Clin Invest. 2002 Apr;109(7):883-93 [11927615.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:383-99 [12432931.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):727-35 [12618527.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19396-405 [12626523.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):143-53 [14607241.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] Clin Nutr. 2004 Apr;23(2):139-51 [15030953.001]
  • [Cites] Endocrinology. 2004 May;145(5):2561-71 [14736730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):889-93 [15159324.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29797-804 [15123663.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):51-65 [4014201.001]
  • [Cites] Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36 [1632423.001]
  • [Cites] Am J Epidemiol. 1992 Jul 15;136(2):192-200 [1415141.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] Pharmacol Ther. 1999 Sep;83(3):217-44 [10576293.001]
  • [Cites] Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S [10617994.001]
  • [Cites] Biochim Biophys Acta. 1995 Sep 14;1258(2):215-23 [7548186.001]
  • [Cites] J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):313-9 [8777575.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2672-9 [8647962.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):779-84 [8896888.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17468-73 [15574495.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Genet Epidemiol. 2005 Feb;28(2):157-70 [15532037.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 [15767339.001]
  • [Cites] Pharmacotherapy. 2005 Jan;25(1):18-25 [15767216.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G361-8 [16195422.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):502-8 [16537708.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12098-102 [16880406.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jan;320(1):22-8 [17008451.001]
  • [Cites] Am J Hum Genet. 2006 Dec;79(6):1002-16 [17186459.001]
  • [Cites] Pharmacogenet Genomics. 2007 Mar;17(3):221-7 [17460551.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1603-13 [17499602.001]
  • [Cites] Pharmacogenet Genomics. 2007 Apr;17(4):295-304 [17496729.001]
  • [Cites] PLoS Genet. 2007 Apr 20;3(4):e58 [17447842.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):232-40 [17290397.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1259-63 [17277229.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 3;359(3):568-73 [17555711.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • (PMID = 20086108.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA123577-02; United States / NCI NIH HHS / CA / R01 CA112516-05; United States / NCI NIH HHS / CA / CA089445-03; United States / NCI NIH HHS / CA / R01 CA089445-03; United States / NCI NIH HHS / CA / R01 CA089445; United States / NCI NIH HHS / CA / R01 CA112516; United States / NCI NIH HHS / CA / R01 CA114467; United States / NCI NIH HHS / CA / R01 CA114467-05; United States / NCI NIH HHS / CA / R03 CA123577; United States / NCI NIH HHS / CA / CA123577-02; United States / NCI NIH HHS / CA / R01 CA114467-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Fatty Acids, Omega-3; 0 / Fish Oils; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS187592; NLM/ PMC2849740
  •  go-up   go-down


43. Moussata D, Nancey S, Lapalus MG, Prost B, Chavaillon A, Bernard G, Ponchon T, Saurin JC: Frequency and severity of ileal adenomas in familial adenomatous polyposis after colectomy. Endoscopy; 2008 Feb;40(2):120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and severity of ileal adenomas in familial adenomatous polyposis after colectomy.
  • BACKGROUND AND STUDY AIMS: The high cumulative risk of colorectal cancer in patients with familial adenomatous polyposis (FAP) justifies prophylactic colectomy with either ileorectal (IRA) or ileal-pouch-anal anastomosis (IPAA).
  • Our aim was to evaluate retrospectively the frequency of and time interval to adenoma development in the ileal mucosa of patients with both types of surgery.
  • RESULTS: In the IPAA group, 18/23 patients (78 %) presented with visible polyps [histology: 16 (70 %) had adenoma with low-grade dysplasia; 1 (4 %) had adenoma with high-grade dysplasia; 1 had normal mucosa].
  • The mean interval between colectomy and the diagnosis of adenoma was 4.7 +/- 3.3 years.
  • In the IRA group, 16/21 patients (77 %) presented visible polyps in the ileal mucosa [adenoma with low-grade dysplasia in 8 patients (38 %), with high-grade dysplasia in 2 (10 %), and lymphoid nodular hyperplasia in 6].
  • The mean interval between colectomy and adenoma diagnosis was significantly shorter in the IPAA than in the IRA group (4.76 +/- 3.3 vs. 16.4 +/- 8.5 years, P< 0.0001).
  • CONCLUSION: Our results show a high frequency of adenomas in the ileal mucosa of patients with IPAA and IRA (74 % and 48 % respectively), with evolution into high-grade dysplasia in 6.7 % of cases.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyposis Coli / surgery. Colectomy / methods. Colonic Pouches / pathology. Ileal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Probability. Proctocolectomy, Restorative. Retrospective Studies. Risk Assessment. Sex Distribution


44. Ranger-Moore J, Frank D, Lance P, Alberts D, Yozwiak M, Bartels HG, Einspahr J, Bartels PH: Karyometry in rectal mucosa of patients with previous colorectal adenomas. Anal Quant Cytol Histol; 2005 Jun;27(3):134-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Karyometry in rectal mucosa of patients with previous colorectal adenomas.
  • In 57 cases recurrent polyps occurred (R cases); in 72 cases no recurrent disease was found at the end of the study (NR cases).
  • After segmentation, feature extraction and selection of a discriminating subset of features, a number of discriminant functions were derived.
  • Also, measures of nuclear abnormality were computed.
  • RESULTS: The differences in karyometricfeature values for nuclei from biopsies of cases with recurrent or nonrecurrent disease were very small and not notably expressed in the majority of nuclei.
  • The distributions of nuclear abnormality values for these subsets of cases were drastically different, with an average value of 1.72 for the group that may be at high risk for another recurrence and 1.02 for the group possibly at low risk.
  • All cases with a prior history of colonic polyps showed a nuclear abnormality deviating from normal.
  • CONCLUSION: Measurement of a sample of 100 nuclei from the rectal mucosa will suggest, for approximately 10% of cases, that a high risk for recurrence of adenomatous polyps exists and, for a slightly lower proportion, confirm that the nuclei deviate only slightly from those from individuals with no history of colonic polyps.
  • For the majority of cases with a prior history of adenoma, the nuclei in the biopsy show a notable deviation from normal, but the deviation is practically the same for cases that had a recurrence and those that did not.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121634.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-41108; United States / NCI NIH HHS / CA / CA-53877-09
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


45. Tublin ME, Pryma DA, Yim JH, Ogilvie JB, Mountz JM, Bencherif B, Carty SE: Localization of parathyroid adenomas by sonography and technetium tc 99m sestamibi single-photon emission computed tomography before minimally invasive parathyroidectomy: are both studies really needed? J Ultrasound Med; 2009 Feb;28(2):183-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of parathyroid adenomas by sonography and technetium tc 99m sestamibi single-photon emission computed tomography before minimally invasive parathyroidectomy: are both studies really needed?
  • Findings of a subsequent Tc 99m sestamibi study were recorded blinded to the sonographic results.
  • Sonography correctly localized a single adenoma or suggested multiglandular disease in 112 of 144 patients (78%).
  • Technetium 99m sestamibi SPECT correctly predicted an adenoma or multiglandular disease in 88 of 144 patients (61%).
  • Five patients with negative sonographic findings were shown to have uniglandular disease on Tc 99m sestamibi SPECT.

  • MedlinePlus Health Information. consumer health - Ultrasound.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168768.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


46. Chiu NC, Wu HM, Chou YH, Li WY, Chiou YY, Guo WY, Chang CY: Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings. AJR Am J Roentgenol; 2007 Nov;189(5):W254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings.
  • OBJECTIVE: Basal cell adenoma is a rare benign epithelial tumor of the salivary gland.
  • The objective of this study is to present the CT findings of parotid basal cell adenoma.
  • We also compare CT findings of basal cell adenoma with those of pleomorphic adenoma, the most common parotid tumor, to determine whether any features on CT can help differentiate these two entities.
  • CONCLUSION: Basal cell adenomas of the parotid gland are located chiefly in the superficial lobe.
  • The age of the patient and the attenuation on unenhanced and contrast-enhanced CT may help in differentiating basal cell adenoma from pleomorphic adenoma of the parotid gland.
  • [MeSH-major] Adenoma / radiography. Adenoma, Pleomorphic / radiography. Parotid Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954621.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Hopkins MH, Fedirko V, Jones DP, Terry PD, Bostick RM: Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial. Cancer Epidemiol Biomarkers Prev; 2010 Mar;19(3):850-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial.
  • In this pilot, randomized, double-blind, placebo-controlled clinical trial (n = 47), we assessed the effects of an antioxidant micronutrient combination (800 mg dl-alpha-tocopherol acetate, 24 mg beta-carotene, 1.0 g vitamin C, 200 microg l-selenomethionine, 7.2 mg riboflavin, 80 mg niacin, 60 mg zinc, 5 mg manganese) given daily over 4 months on oxidative and inflammatory biomarkers in patients with a history of sporadic colorectal adenoma.
  • Plasma tumor necrosis factor-alpha (TNF-alpha), interleukin-6, and F2-isoprostane concentrations were measured using ELISAs, and cystine (CySS) was measured using high-performance liquid chromatography.
  • [MeSH-major] Adenoma / drug therapy. Antioxidants / therapeutic use. Colorectal Neoplasms / drug therapy. Micronutrients / therapeutic use. Oxidative Stress / drug effects
  • [MeSH-minor] Adult. Aged. Ascorbic Acid / administration & dosage. Biomarkers, Tumor / analysis. Chromatography, High Pressure Liquid. Cystine / blood. Double-Blind Method. Enzyme-Linked Immunosorbent Assay. F2-Isoprostanes / blood. Female. Humans. Interleukin-6 / blood. Male. Manganese / administration & dosage. Middle Aged. Niacin / administration & dosage. Pilot Projects. Riboflavin / administration & dosage. Selenomethionine / administration & dosage. Tumor Necrosis Factor-alpha / blood. Vitamin E / administration & dosage. Zinc / administration & dosage. beta Carotene / administration & dosage

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. Riboflavin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200432.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / F2-Isoprostanes; 0 / Interleukin-6; 0 / Micronutrients; 0 / Tumor Necrosis Factor-alpha; 01YAE03M7J / beta Carotene; 1406-18-4 / Vitamin E; 2679MF687A / Niacin; 42Z2K6ZL8P / Manganese; 48TCX9A1VT / Cystine; 964MRK2PEL / Selenomethionine; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid; TLM2976OFR / Riboflavin
  •  go-up   go-down


48. Iyengar P, Cody HS 3rd, Brogi E: Pleomorphic adenoma of the breast: case report and review of the literature. Diagn Cytopathol; 2005 Dec;33(6):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast: case report and review of the literature.
  • Pleomorphic adenoma of the breast (PAB) is a very rare neoplasm.
  • On cytologic material, fibroadenoma and phyllodes tumor should also be considered within the differential diagnosis.
  • Correct identification of this benign mammary neoplasm is important to avoid unnecessarily aggressive treatment.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16299746.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Yen AM, Chen TH, Duffy SW, Chen CD: Incorporating frailty in a multi-state model: application to disease natural history modelling of adenoma-carcinoma in the large bowel. Stat Methods Med Res; 2010 Oct;19(5):529-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporating frailty in a multi-state model: application to disease natural history modelling of adenoma-carcinoma in the large bowel.
  • Homogeneous multi-state models of disease progression have been widely used for designing and evaluating cancer screening programs.
  • We applied these to the example of progression of adenoma to colorectal cancer in a three-state model and to a five-state model including consideration of adenoma size.
  • Results were compared with those of purely homogeneous models in a previous study in terms of cumulative risk of malignant transformation from adenoma to invasive colorectal cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20488838.001).
  • [ISSN] 1477-0334
  • [Journal-full-title] Statistical methods in medical research
  • [ISO-abbreviation] Stat Methods Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, Okanoue T, Hattori T: Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci; 2005 Sep;50(9):1741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.
  • The entity of serrated adenoma of the colorectum was first proposed in 1990, and it was characterized as epithelial neoplasia combining the architectural features of a hyperplastic polyp with the cytological features of an adenoma.
  • Over the past few years, various clinicopathological studies on serrated adenoma have been reported, but its histogenesis remains unclear.
  • Recently the existence of a "serrated neoplasia pathway" leading to malignancy, which is different from the so-called adenoma-carcinoma sequence, has been discussed.
  • Yao et al. reported that hyperplastic polyps and serrated adenomas share a common cell lineage with gastric differentiation.
  • To clarify the existence of the serrated neoplasia pathway, we performed immunohistochemical staining of cytokeratin 7 (CK7) and cytokeratin 20 (CK20), which are commonly used to determine the primary site of a metastatic lesion, and we examined the pattern of CK7/CK20 expression in various colorectal lesions including 44 serrated adenomas, 25 hyperplastic polyps, 20 traditional adenomas, and 48 carcinomas.
  • An obvious difference existed in the pattern of CK7/CK20 expression between the serrated lesions (hyperplastic polyps and serrated adenomas) and others.
  • The majority of serrated adenomas and hyperplastic polyps presented a CK7+/CK20+ pattern, whereas most conventional adenomas and adenocarcinomas expressed CK7-/CK20+.
  • Adenocarcinoma developing in serrated adenoma also presented a CK7+/CK20+ pattern.
  • Taken together with the present results, a distinct pathway of colorectal carcinogenesis must exist, which is different from the adenoma-carcinoma sequence.
  • CK7 is a possible marker for the serrated neoplasia pathway of colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Intermediate Filament Proteins / biosynthesis. Keratins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] J Pathol. 2000 Mar;190(4):444-9 [10699993.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Acta Histochem. 1991;91(1):21-3 [1724863.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Gut. 2002 Aug;51(2):200-6 [12117880.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):512-22 [11710638.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:282-306 [2417517.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):445-54 [11962749.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):215-20 [11328539.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] J Pathol. 1999 Apr;187(5):511-7 [10398114.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):758-63 [11937308.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] J Pathol. 1991 Oct;165(2):145-52 [1720817.001]
  • (PMID = 16133982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


51. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The targeting of solid tumors requires delivery tools that resist intracellular and extracellular inactivation, and that are taken up specifically by tumor cells.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • Of a given tumor sample, on average, 80% of the cells could visibly bind STxB, and upon incubation at 37 degrees C, STxB was transported to the Golgi apparatus, following the retrograde route.
  • This STxB-specific intracellular targeting allows the molecule to avoid recycling and degradation, and STxB could consequently be detected on tumor cells even 5 days after initial uptake.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


52. Kim K, Park U, Wang J, Lee J, Park S, Kim S, Choi D, Kim C, Park J: Gene profiling of colonic serrated adenomas by using oligonucleotide microarray. Int J Colorectal Dis; 2008 Jun;23(6):569-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling of colonic serrated adenomas by using oligonucleotide microarray.
  • To elucidate the molecular genetic basis of the serrated pathway, we performed an initial oligonucleotide microarray to analyze the gene expression pattern of patients with colonic serrated adenomas.
  • METHODS: Oligonucleotide microarrays containing 3,096 genes were used to compare individual gene profiles of serrated adenoma samples (n = 5) and normal mucosal samples obtained from colon in patients by colonoscopy.
  • CONCLUSION: Although our report presents only preliminary results, we think they provide important data regarding serrated adenomas not only to better define the precise mechanism of genetic changes involved as the main member in serrated pathway of colorectal carcinogenesis but also to yield practical information for identifying optimized diagnostic modalities.
  • [MeSH-major] Adenoma / genetics. Carrier Proteins / genetics. Colonic Neoplasms / genetics. Gene Expression Profiling. Membrane Proteins / genetics. Receptors, Retinoic Acid / genetics. Receptors, Tumor Necrosis Factor / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Microsc Res Tech. 2000 Aug 1;50(3):184-95 [10891884.001]
  • [Cites] Gastroenterology. 1991 Apr;100(4):1142-3 [2001817.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3544-9 [11325815.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2238-48 [16228831.001]
  • [Cites] Gut. 1992 Apr;33(4):518-23 [1582597.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):929-33 [11920460.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):170-8 [15389252.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):63-8; discussion 69 [11223827.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Dec 14;289(4):876-81 [11735128.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):23009-17 [11294831.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3391-400 [9699671.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1377-91 [14973550.001]
  • [Cites] Pathol Int. 2003 May;53(5):277-83 [12713561.001]
  • [Cites] J Clin Pathol. 1999 Jun;52(6):455-60 [10562815.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):417-23 [9130988.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Methods Mol Med. 2003;71:135-46 [12374018.001]
  • [Cites] Gut. 1997 May;40(5):660-3 [9203947.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6571-4 [14583447.001]
  • [Cites] J Cell Biochem. 2000 Apr;77(4):604-14 [10771516.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1169-78 [7505205.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):323-32 [10930367.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 3;285(5):1244-9 [11478790.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):141-52 [15043283.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):481-5 [14994108.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1309-13 [11005503.001]
  • [Cites] Am J Gastroenterol. 1989 Feb;84(2):113-7 [2916517.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):213-25 [11157777.001]
  • [Cites] Exp Mol Pathol. 2006 Apr;80(2):165-70 [16202996.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):682-6 [15220357.001]
  • [Cites] Gut. 1998 May;42(5):680-4 [9659164.001]
  • [Cites] Oncol Rep. 2004 May;11(5):957-63 [15069532.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1932-41 [11919254.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • [Cites] Lancet. 1983 Jan 1;1(8314-5):28-30 [6129371.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1731-7 [15550577.001]
  • (PMID = 18305945.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / MALL protein, human; 0 / Membrane Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / RARA protein, human; 0 / Receptors, Retinoic Acid; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Retinoic Acid Receptor alpha; 0 / TNFRSF10A protein, human
  •  go-up   go-down


53. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.
  • Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.
  • Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways.
  • Abundant PTTG in GH-secreting pituitary adenomas also triggers p21-dependent senescence.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down


54. Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML: Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery; 2008 Jun;62(6):1262-9; discussion 1269-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study evaluates the safety and efficacy of gamma knife radiosurgery (GKRS) in patients with a growth hormone-secreting adenoma.
  • Tumor volume was also assessed.
  • A decrease in tumor volume control was achieved in 83 (92%) of 90 patients.
  • Five patients (6%) had no change in tumor volume, and two patients (2%) had an increase in tumor volume.
  • CONCLUSION: GKRS is a complementary treatment for recurrent or residual growth hormone-secreting pituitary adenomas.
  • Although infrequent, tumor growth, new-onset pituitary hormone deficiency, recurrence, and neurological dysfunction require careful clinical, radiological, and endocrinological follow-up.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Radiosurgery


55. Young PE, Gentry AB, Cash BD: The utility of flexible sigmoidoscopy after a computerized tomographic colonography revealing only rectosigmoid lesions. Aliment Pharmacol Ther; 2008 Mar 15;27(6):520-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine the prevalence of advanced proximal colonic neoplasia when computerized tomographic colonography reveals only rectosigmoid polyps, and characterize the yield of polypectomy via flexible sigmoidoscopy in such patients.
  • Advanced lesions were defined as: adenocarcinoma, tubular adenoma >1 cm, > or =3 tubular adenomas, tubulovillous histology or high-grade dysplasia.
  • Advanced proximal neoplasia occurred in 2% (three of 203) with only rectosigmoid polyps on computerized tomographic colonography.
  • This strategy carries a small risk of missed proximal advanced neoplasia.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194507.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Kajitani T, Liu S, Maruyama T, Uchida H, Sakurai R, Masuda H, Nagashima T, Ono M, Arase T, Yoshimura Y: Analysis of serum FSH bioactivity in a patient with an FSH-secreting pituitary microadenoma and multicystic ovaries: A case report. Hum Reprod; 2008 Feb;23(2):435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FSH-secreting pituitary adenoma (FSHoma) is often associated with increased levels of serum FSH and ovarian hyperstimulation syndrome (OHSS).
  • OHSS may result not from increased FSH levels, but also from increased bioactivity of the FSH derived from the adenoma.
  • To address this, we measured the FSH bioactivity in the serum of a 40-year-old woman with an FSHoma and OHSS, whose FSH levels were normal.
  • The responsiveness was further augmented by co-addition of a 3-methyl isobutylxanthine, which improved the sensitivity of our assay.
  • [MeSH-major] Adenoma / metabolism. Follicle Stimulating Hormone, Human / blood. Follicle Stimulating Hormone, Human / secretion. Ovarian Hyperstimulation Syndrome / metabolism. Pituitary Neoplasms / metabolism. Polycystic Ovary Syndrome / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056718.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Follicle Stimulating Hormone, Human; EC 1.13.12.- / Luciferases; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


57. Tachezy R, Jirasek T, Salakova M, Ludvikova V, Kubecova M, Horak L, Mandys V, Hamsikova E: Human papillomavirus infection and tumours of the anal canal: correlation of histology, PCR detection in paraffin sections and serology. APMIS; 2007 Mar;115(3):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our recent study the presence of HPV was detected by PCR in biopsy specimens of 42 different anal tumours, including SCCA and its histological variants (n=22), adenocarcinomas (n=5), tubulovillous adenomas (n=5) and anal condylomas (n=10).
  • Two adenomas showed presence of HPV16; one showed simultaneous positivity for HPV33.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HPV.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367464.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 9004-22-2 / Globins
  •  go-up   go-down


58. Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, Hatakeyama D, Fujitsuka H, Yamashita T, Shibata T: Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg; 2005 Jul;34(5):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases.
  • We present a retrospective study of 82 patients with intraoral minor salivary gland tumors which were diagnosed from 1979 to 2003 in Gifu University Hospital.
  • A total of 82 tumors, consisting of 55 benign and 27 malignant tumors, were found in 28 male and 54 female Japanese patients; the male-to-female ratio was 1:1.9.
  • Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).
  • From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053873.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


59. Grady WM: Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans; 2005 Aug;33(Pt 4):684-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas.
  • These hypermethylated genes are not only probable pathogenic events affecting colon-cancer formation, but also neoplasm-specific molecular events that may be useful as molecular markers for colon tumours.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042574.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 33
  •  go-up   go-down


60. Park BK, Kim B, Ko K, Jeong SY, Kwon GY: Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: pathological correlation. Eur Radiol; 2006 Mar;16(3):642-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: pathological correlation.
  • OBJECTIVES: To assess the accuracy of CT for the diagnosis of histologically confirmed adrenal adenoma and nonadenoma using CT numbers.
  • MATERIALS AND METHODS: Our study included 91 adrenal masses in 83 patients; histopathological diagnoses were 45 adenomas, 31 pheochromocytomas, 6 hyperplasias, 4 metastasis, and 5 miscellaneous lesions.
  • RESULTS: Sensitivity, specificity, and accuracy for adenoma were 40% (18/45), 91% (42/46), and 66% (60/91) with unenhanced CT, and 96% (24/25), 61% (11/18), and 81% (35/43) with DCE CT.
  • Adrenal masses falsely diagnosed as adenoma on unenhanced CT included three hyperplasias and one endothelial cyst, and those falsely diagnosed as adenoma on DCE CT were five pheochromocytomas, one oncocytic cortical tumor, and one primary pigmented nodular adrenocortical dysplasia.
  • Twenty-five lipid-poor adenomas were falsely diagnosed as nonadenomas on unenhanced CT and one degenerated adenoma both on unenhanced CT and on DCE CT.
  • CONCLUSION: Diagnosing adenoma merely on CT numbers can lead to misdiagnosis.
  • [MeSH-major] Adenoma / diagnostic imaging. Adrenal Gland Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Analysis of Variance. Contrast Media. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Hyperplasia. Male. Middle Aged. Neoplasm Metastasis. Pheochromocytoma / diagnostic imaging. Pheochromocytoma / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur Radiol. 2006 Mar;16(3):768
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):843-9 [12933492.001]
  • [Cites] Endocr J. 2004 Feb;51(1):89-95 [15004414.001]
  • [Cites] Radiology. 2005 Feb;234(2):479-85 [15671003.001]
  • [Cites] Radiology. 1998 May;207 (2):369-75 [9577483.001]
  • [Cites] Am J Med. 1996 Jul;101(1):88-94 [8686720.001]
  • [Cites] Radiology. 1996 Sep;200(3):743-7 [8756925.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):997-1002 [10587135.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1787-92 [15241622.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):201-4 [9648789.001]
  • [Cites] Radiology. 1997 Mar;202(3):693-6 [9051018.001]
  • [Cites] Radiology. 2000 Dec;217(3):798-802 [11110946.001]
  • [Cites] J Comput Assist Tomogr. 1994 May-Jun;18(3):432-8 [8188912.001]
  • [Cites] Radiology. 2002 Mar;222(3):629-33 [11867777.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1453-9 [7484585.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1411-5 [11044054.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):747-52 [9490968.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):520-6 [10022410.001]
  • (PMID = 16215735.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


61. Shevchenko IuL, Vetshev PS, Kovalenko EI, Vetshev SL: [The long-term results of the dynamic observation of patients with adrenal gland adenomas]. Klin Med (Mosk); 2006;84(8):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The long-term results of the dynamic observation of patients with adrenal gland adenomas].
  • The authors demonstrate the results of many years of observing patients with hormone-inactive adrenal gland adenomas.
  • The study shows that slow growth is generally typical of these adenomas.
  • The study demonstrates that long existence of adenomas do not aggravate the clinical course of arterial hypertension and diabetes mellitus, and do not express any hormonal activity.
  • [MeSH-major] Adrenocortical Adenoma / pathology
  • [MeSH-minor] Aged, 80 and over. Body Mass Index. Disease Progression. Female. Humans. Hydrocortisone / blood. Male. Middle Aged. Obesity / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087195.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


62. Glazer E, Golla V, Forman R, Zhu H, Levi G, Bodenheimer HC Jr: Serrated adenoma is a risk factor for subsequent adenomatous polyps. Dig Dis Sci; 2008 Aug;53(8):2204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated adenoma is a risk factor for subsequent adenomatous polyps.
  • BACKGROUND: Serrated adenomas (SA) are histologically defined by the presence of both hyperplastic and adenomatous features.
  • This study was undertaken to define the relationship between SA and the future development of adenomatous polyps.
  • METHODS: Colonoscopic biopsies that contained a pathologic diagnosis of SA were identified from a pathology database of a major urban academic medical center.
  • On follow-up examination four patients (24%) and no controls had adenomatous polyps (P = 0.01).
  • Serrated adenomas appear to be found more commonly in the left colon and in older patients.
  • This study found a significant association between SA and the subsequent development of adenomatous polyps.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Case-Control Studies. Colonoscopy. Disease Progression. Female. Humans. Hyperplasia. Male. Middle Aged. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Am J Surg Pathol. 1984 Jul;8(7):551-6 [6742315.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):349-59 [15716230.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10 (9):3082-90 [15131047.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2242-55 [15555008.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1300-9 [11729109.001]
  • [Cites] J Pathol. 2001 Mar;193(3):286-94 [11241406.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17 ):1307-13 [11535705.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] Science. 1989 Apr 14;244(4901):207-11 [2565047.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1141-7 [10810411.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Gastrointest Endosc. 1995 Aug;42(2):114-22 [7590045.001]
  • (PMID = 18320324.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Bellut D, Hlavica M, Schmid C, Bernays RL: Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly. Neurosurg Focus; 2010 Oct;29(4):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Acromegaly is a rare disease, usually caused by a growth hormone (GH)-producing pituitary adenoma.
  • In the present study, the contribution of ultra-low-field (0.15-T) iMR imaging to tumor resection, complication avoidance, and endocrinological and neurological outcome was analyzed.
  • METHODS: A series of 39 consecutive transsphenoidal iMR imaging-guided (using the PoleStar N20 device) surgical procedures performed between September 2005 and August 2009 for GH-producing pituitary adenomas was retrospectively analyzed.
  • RESULTS: Thirty-seven patients with acromegaly underwent 39 transsphenoidal surgeries for pituitary adenomas.
  • Detection of tumor remnant on iMR imaging led to a 5.1% increase in remission rate.
  • CONCLUSIONS: In this largest study to date of GH-producing pituitary adenomas in which iMR imaging-guided transsphenoidal surgery was analyzed, the results suggest that this method is a highly effective and safe treatment modality, even compared with previously published surgical series in which high-field iMR imaging was used.
  • Limitations of iMR imaging are the detection of small residual tumor in the cavernous sinus and persisting disease that could not be observed, even on diagnostic high-field follow-up MR images.
  • [MeSH-major] Acromegaly / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Intraoperative Care / methods. Magnetic Resonance Imaging / methods. Neurosurgical Procedures / methods
  • [MeSH-minor] Adenoma / surgery. Adult. Female. Follow-Up Studies. Human Growth Hormone / secretion. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm, Residual / diagnosis. Pituitary Neoplasms / surgery. Remission Induction. Sphenoid Sinus. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887134.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


64. Kronborg O, Jørgensen OD, Fenger C, Rasmussen M: Three randomized long-term surveillance trials in patients with sporadic colorectal adenomas. Scand J Gastroenterol; 2006 Jun;41(6):737-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three randomized long-term surveillance trials in patients with sporadic colorectal adenomas.
  • OBJECTIVE: Guidelines for surveillance of patients with previous sporadic colorectal adenomas are based on retrospective long-term follow-up and prospective short-term studies.
  • The aim of the present studies was to compare relative risk (RR) of new neoplasia as well as complications, using different intervals between examinations in long-term surveillance.
  • MATERIAL AND METHODS: Between l98l and l991, patients with pedunculated and small, flat and sessile adenomas were allocated at random to a 24 months (group A) or 48 months (group B) interval between surveillance colonoscopies (n=671).
  • Patients with flat and sessile adenomas greater than 5 mm in diameter were randomized to intervals of 6 months (group C) or 12 months (group D) between l981 and 1987 (n=73).
  • Finally, 200 patients with similar adenomas as in groups C and D were randomized to 12 months (group E) or 24 months (group F) from 1988 to 2000.
  • RESULTS: Advanced adenomas were equally as frequent in group A and group B, but colorectal cancer (CRC) was found significantly more often in group B (RR = 6.2 (1.0-117.4)).
  • Advanced new adenomas tended to be more frequent in group D than in C (p=0.08), but only one CRC was detected and this was in group C.
  • CONCLUSIONS: The results suggest that 2-year intervals should be used between colonoscopies in patients with previous pedunculated adenomas and small, flat and sessile adenomas, whereas larger, flat and sessile adenomas may need intervals of 1 year.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Population Surveillance

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716975.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  •  go-up   go-down


65. Cohen M, Thomson M, Taylor C, Donatone J, Quijano G, Drut R: Colonic and duodenal flat adenomas in children with classical familial adenomatous polyposis. Int J Surg Pathol; 2006 Apr;14(2):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic and duodenal flat adenomas in children with classical familial adenomatous polyposis.
  • Flat adenomas of the colon and duodenum have been described as associating with familial adenomatous polyposis (FAP), its attenuated variant, and the so-called hereditary nonpolyposis colorectal cancer.
  • There seem to be no report on the occurrence of flat adenomas in pediatric patients with family history of FAP.
  • We are reporting 4 children from 2 cancer-prone families in whom colonic and duodenal moderately dysplastic flat adenomas were found.
  • Microscopic study demonstrated tubular adenomas with a few neoplastic crypts, slight disarray of the overall architecture, and moderate (low-grade) dysplasia of the epithelium.
  • These features were more obvious at the center and superficial areas of the adenomas.
  • The 4 children had multiple flat adenomas of the colon and duodenum (2/4) matching with those described in adult patients.
  • Flat adenomas in the context of FAP probably represent early stages of the adenoma development.
  • [MeSH-major] Adenoma / etiology. Adenomatous Polyposis Coli / complications. Colorectal Neoplasms / etiology. Duodenal Neoplasms / etiology. Precancerous Conditions / etiology


66. Donangelo I, Marcos HP, Araújo PB, Marcondes J, Filho PN, Gadelha M, Chimelli L: Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr Pathol; 2005;16(1):53-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas.
  • The retinoblastoma gene (RB1) is a tumor-suppressor gene in chromosomal region 13q14.2.
  • Some studies have shown that losses in this chromosomal region are related to aggressive tumor behavior, although the retinoblastoma protein (pRB) is still expressed.
  • Conversely, lack of expression of pRB was observed in one fourth of GH-secreting pituitary adenomas (GH-tumors).
  • In 10 tumors (20% of total) the adenomatous cells were negative (5 cases) or had very low labeling (5 cases) for pRB.
  • Sixty three percent (31/49) of the tumors showed staining in 10-80% of the cells and in 16% (8/49) of the cases >80% of the adenomatous cells were positive for pRB.
  • In conclusion, pRB is underexpressed in a subgroup of GH-tumors, and this may represent an early event in the pathogenesis of this tumor subtype.
  • [MeSH-major] Adenoma / secretion. Human Growth Hormone / secretion. Pituitary Gland, Anterior / secretion. Pituitary Neoplasms / secretion. Retinoblastoma Protein / metabolism

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 1998 May;157(2):337-41 [9659297.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):491-6 [7959682.001]
  • [Cites] Hum Mol Genet. 2001 Jun 1;10(12):1275-85 [11406609.001]
  • [Cites] Pituitary. 2003 Sep;6(2):75-80 [14703016.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7942-9 [12970742.001]
  • [Cites] Cancer Lett. 1998 Apr 24;126(2):209-14 [9585068.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):573-6 [10366412.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1386-93 [8339229.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1388-91 [9543172.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):387-92 [8106627.001]
  • [Cites] J Biol Chem. 2003 Mar 21;278(12):10824-30 [12531887.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):401-7 [9033255.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1021-7 [8134105.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):644-6 [7690360.001]
  • [Cites] FEBS Lett. 1998 Apr 17;426(2):266-70 [9599022.001]
  • [Cites] J Endocrinol Invest. 2000 May;23(5):304-9 [10882148.001]
  • [Cites] J Pediatr Endocrinol Metab. 1999 May-Jun;12(3):381-7 [10821217.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):922-7 [8157722.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):44-50 [10389976.001]
  • [Cites] Endocr Pathol. 1995 Autumn;6(3):189-196 [12114739.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5446-51 [9407947.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):693-6 [8033049.001]
  • [Cites] Genomics. 2002 Jul;80(1):5-7 [12079276.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2631-4 [9709923.001]
  • [Cites] Eur J Endocrinol. 1996 Jun;134(6):720-6 [8766942.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1562-6 [10197629.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):250-5 [10216521.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1613-6 [7712461.001]
  • [Cites] Oncogene. 1993 Apr;8(4):1063-7 [8455933.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2815-21 [8514889.001]
  • [Cites] Oncol Res. 2001;12(11-12):491-500 [11939413.001]
  • [Cites] Science. 1990 Aug 10;249(4969):655-9 [2116665.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] J Pathol. 1999 Jun;188(2):168-73 [10398160.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):509-19 [9250163.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6567-72 [12242654.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1421-6 [1977758.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):818-24 [9062489.001]
  • [Cites] Am J Hum Genet. 1991 May;48(5):880-8 [1673287.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3210-2 [9745428.001]
  • [Cites] Microsc Res Tech. 2002 Oct 1;59(1):68-83 [12242698.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):141-50 [12580928.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3141-7 [9284759.001]
  • [Cites] Eur J Biochem. 1997 Jun 15;246(3):581-601 [9219514.001]
  • [Cites] Cancer Lett. 1999 Sep 20;144(1):85-92 [10503881.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Oct;129(4):301-6 [8237246.001]
  • (PMID = 16000847.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


67. Giorgi RR, Correa-Giannella ML, Casarini AP, Machado MC, Bronstein MD, Cescato VA, Giannella-Neto D: Metallothionein isoform 3 gene is differentially expressed in corticotropin-producing pituitary adenomas. Neuroendocrinology; 2005;82(3-4):208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein isoform 3 gene is differentially expressed in corticotropin-producing pituitary adenomas.
  • In order to search for candidate genes related to pituitary adenoma aggressiveness, the present investigation was intended to compare the mRNA expression profile from a pool of four nonfunctional pituitary adenomas (NFPA) with a spinal cord metastasis of a nonfunctional pituitary carcinoma (MNFPC).
  • The metallothionein isoform 3 (MT3) gene was differentially expressed in nonfunctional adenomas in comparison to the metastasis of nonfunctional carcinoma.
  • A microarray dataset comprising 19,881 probes was employed for comparing expression profiles of a spinal cord metastasis of a nonfunctional pituitary carcinoma with a pool of four nonfunctional pituitary adenomas.
  • RT-qPCR confirmed the microarray findings and was used to investigate MT3 mRNA gene expression in tumor samples of a series of 52 different pituitary adenoma subtypes comprising 10 corticotropin (ACTH)-producing, 18 growth hormone (GH)-producing, 8 prolactin (PRL)-producing, and 16 nonfunctional adenomas.
  • MT3 mRNA expression was statistically significantly higher in ACTH-producing pituitary adenomas and in nonfunctional pituitary adenomas in comparison to the other pituitary adenoma subtypes.
  • The more abundant expression of this gene in ACTH-producing pituitary adenomas suggests that MT3 could be related to distinct pituitary cell lineage regulating the activity of some transcription factor of importance in hormone production and/or secretion.
  • [MeSH-major] Adenoma / metabolism. Adrenocorticotropic Hormone / metabolism. Nerve Tissue Proteins / biosynthesis. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601360.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / growth inhibitory factor; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


68. Hiraoka S, Kato J, Fujiki S, Kaji E, Morikawa T, Murakami T, Nawa T, Kuriyama M, Uraoka T, Ohara N, Yamamoto K: The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology; 2010 Nov;139(5):1503-10, 1510.e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: There is evidence that serrated polyps (serrated adenomas and hyperplastic polyps) have different malignant potential than traditional adenomas.
  • We used a colonoscopy database to determine the association between the presence of serrated colorectal polyps and colorectal neoplasia.
  • Serrated polyps were defined as those diagnosed by the pathologists in the participating hospitals as a serrated lesion (a lesion given the term of "classical hyperplastic polyp," "traditional serrated adenoma," "sessile serrated adenoma," or "mixed serrated polyp").
  • RESULTS: There were 1573 patients (15.4%) with advanced neoplasia, 708 patients (6.9%) with colorectal cancer (CRC), and 140 patients (1.4%) with LSPs in our cohort.
  • Multivariate analysis associated the presence of LSPs with advanced neoplasia (odds ratio [OR], 4.01; 95% confidence interval [CI], 2.83-5.69) and CRC (OR, 3.34; 95% CI, 2.16-5.03).
  • [MeSH-major] Adenoma / epidemiology. Colonic Polyps / epidemiology. Colonoscopy / methods. Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Diagnosis, Differential. Disease Progression. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Sex Distribution

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Gastroenterology. 2010 Nov;139(5):1444-7 [20875785.001]
  • (PMID = 20643134.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


69. Nogueira EF, Gerry D, Mantero F, Mariniello B, Rainey WE: The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clin Endocrinol (Oxf); 2010 Jul;73(1):22-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas.
  • Genetic deletion of subunits of K+-selective leak-channels (KCNK), TASK1 and/or TASK3, in mice generates animals with hyperaldosteronism and histological changes in the adrenal cortex.
  • DESIGN: TASK1 expression was investigated by comparative microarray analysis of aldosterone-producing adenomas (APA) and normal adrenals (NAs).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Endocrinol (Paris). 2000 Feb;61(1):52-60 [10790593.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1863-7 [10843166.001]
  • [Cites] J Mol Endocrinol. 2009 Apr;42(4):319-30 [19158234.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1480-6 [18854423.001]
  • [Cites] Lancet. 2008 Jun 7;371(9628):1921-6 [18539224.001]
  • [Cites] Rev Esp Cardiol. 2008 Apr;61(4):418-21 [18405523.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):133-54 [18292466.001]
  • [Cites] J Hypertens. 2008 Apr;26(4):613-21 [18327065.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2203-8 [18250325.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):863-74 [10847588.001]
  • [Cites] Nat Rev Neurosci. 2001 Mar;2(3):175-84 [11256078.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):157-71 [11325526.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Aug;281(2):C700-8 [11443069.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5426-32 [11733509.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):621-9 [11875121.001]
  • [Cites] Hypertension. 2003 Aug;42(2):161-5 [12796282.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5403-11 [14532113.001]
  • [Cites] J Neurophysiol. 2003 Oct;90(4):2341-8 [12815014.001]
  • [Cites] Physiol Rev. 2004 Apr;84(2):489-539 [15044681.001]
  • [Cites] J Steroid Biochem. 1974 Aug;5(5):501-23 [4376199.001]
  • [Cites] Clin Sci Mol Med. 1975 Dec;49(6):527-34 [1204282.001]
  • [Cites] Steroids. 1978 Sep;32(2):257-67 [715820.001]
  • [Cites] Annu Rev Physiol. 1988;50:409-26 [3288099.001]
  • [Cites] Endocrinology. 1991 May;128(5):2534-9 [2019265.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2235-40 [8404675.001]
  • [Cites] Ann Intern Med. 1994 Dec 1;121(11):877-85 [7978702.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Feb;42(2):111-9 [7704954.001]
  • [Cites] Steroids. 1995 Jan;60(1):2-9 [7792810.001]
  • [Cites] Mol Cell Endocrinol. 1995 Dec 29;115(2):215-19 [8824897.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Jul;58(4):417-24 [8903426.001]
  • [Cites] Endocrinology. 1997 Feb;138(2):835-8 [9003023.001]
  • [Cites] Steroids. 1997 Jan;62(1):10-20 [9029709.001]
  • [Cites] J Membr Biol. 1997 Apr 1;156(3):261-77 [9096067.001]
  • [Cites] Mol Endocrinol. 1997 May;11(5):638-49 [9139807.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4167-75 [9322926.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 2):F674-83 [10330049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3422-7 [16492788.001]
  • [Cites] Mol Endocrinol. 2006 May;20(5):953-70 [16141358.001]
  • [Cites] Hypertension. 2006 Aug;48(2):232-8 [16801482.001]
  • [Cites] J Physiol. 2007 Jan 15;578(Pt 2):377-85 [17068099.001]
  • [Cites] Cell Biochem Biophys. 2007;47(2):209-56 [17652773.001]
  • [Cites] J Mol Endocrinol. 2007 Dec;39(6):365-74 [18055484.001]
  • [Cites] EMBO J. 2008 Jan 9;27(1):179-87 [18034154.001]
  • (PMID = 19878209.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK043140; United States / NIDDK NIH HHS / DK / R01 DK043140-16S1; United States / NIDDK NIH HHS / DK / DK43140
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KCNK1 protein, human; 0 / Kcnk1 protein, mouse; 0 / Nerve Tissue Proteins; 0 / Potassium Channels, Tandem Pore Domain; 0 / RNA, Small Interfering; 0 / potassium channel subfamily K member 3; 4964P6T9RB / Aldosterone; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  • [Other-IDs] NLM/ NIHMS156002; NLM/ PMC4158746
  •  go-up   go-down


70. Bleier BS, LiVolsi VA, Chalian AA, Gimotty PA, Botbyl JD, Weber RS: Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas. Arch Otolaryngol Head Neck Surg; 2006 Jul;132(7):779-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas.
  • OBJECTIVE: A subset of parathyroid adenomas contains a relative overabundance of oxyphil cells that are capable of greater technetium Tc 99m sestamibi tracer uptake and retention than other cell types.
  • We examined whether the presence of oxyphil cells augments the sensitivity of technetium Tc 99m sestamibi preoperative localization and whether the histologic findings of a lesion could be predicted based on the adenoma mass and serum calcium and parathyroid hormone levels.
  • DESIGN: Retrospective, single-blinded comparison of technetium Tc 99m sensitivity rates, lesion mass, and preoperative serum calcium and parathyroid hormone values of patients with chief and mixed cell-dominant adenomas and those with oxyphil-dominant parathyroid adenomas.
  • PATIENTS: Sixty-three patients diagnosed as having a parathyroid adenoma.
  • INTERVENTION: All patients underwent resection of a parathyroid adenoma following a preoperative technetium Tc 99m sestamibi localization study and serum calcium and parathyroid hormone level analysis.
  • CONCLUSIONS: Oxyphil cell predominance within an adenoma augments technetium Tc 99m sestamibi scan sensitivity in a statistically significant manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847189.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA16520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


71. Zermani R, Chelbi E, Farah F, Rameh S, Kourda N, Ferchichi L, Sayari S, Zaouche A, Ben Jilani S: [Serrated adenoma of the appendix associated with colonic adenocarcinoma]. Tunis Med; 2009 Jan;87(1):97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serrated adenoma of the appendix associated with colonic adenocarcinoma].
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Appendiceal Neoplasms / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522437.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


72. Sanduleanu S, Driessen A, Gomez-Garcia E, Hameeteman W, de Bruïne A, Masclee A: In vivo diagnosis and classification of colorectal neoplasia by chromoendoscopy-guided confocal laser endomicroscopy. Clin Gastroenterol Hepatol; 2010 Apr;8(4):371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo diagnosis and classification of colorectal neoplasia by chromoendoscopy-guided confocal laser endomicroscopy.
  • BACKGROUND & AIMS: Colorectal cancer surveillance guidelines rely on clinicohistologic features of adenomas.
  • The aims of this study were (1) to define and validate differential features of adenomatous and nonadenomatous colorectal polyps by chromoendoscopy-guided CLE (C-CLE) and (2) to assess predictive value of this technique for diagnosis of colorectal neoplasia.
  • Ex vivo histology showed 68 adenomas, 6 invasive carcinomas, 30 hyperplastic polyps, and 12 inflammatory polyps.
  • C-CLE of adenomas revealed lack of epithelial surface maturation, crypt budding, altered vascular pattern, and loss of cell polarity.
  • Adenoma dysplasia score reliably discriminated high-grade dysplasia from low-grade dysplasia (accuracy, 96.7%).
  • CONCLUSIONS: C-CLE accurately discriminates adenomatous from nonadenomatous colorectal polyps and enables evaluation of degree of dysplasia during ongoing endoscopy.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Clin Gastroenterol Hepatol. 2010 Apr;8(4):318-21 [20026427.001]
  • (PMID = 19683597.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Nosho K, Yoshida M, Yamamoto H, Taniguchi H, Adachi Y, Mikami M, Hinoda Y, Imai K: Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis; 2005 May;26(5):892-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is now becoming clear that matrix metalloproteinases (MMPs) play a key role in tumor development and growth.
  • MMPs are overexpressed in a variety of premalignant tumor tissues, including colorectal adenoma.
  • Little is known about the mechanisms underlying the overexpression of MMPs in adenoma tissues.
  • The aim of this study was to examine the E1AF expression and determine whether it is correlated with the expression of MMPs, COX-2 and inducible nitric oxide synthase (iNOS) in human colorectal adenoma and submucosal cancer (pT1).
  • Using the semi-quantitative RT-PCR, 90 colorectal tumors, including 63 adenomas and 27 cancers (pT1), were analyzed for the expression of E1AF, MMPs, COX-2 and iNOS.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695237.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / ETV4 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Transcription Factors; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


74. Armah HB, Krasinskas AM, Parwani AV: Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case. Diagn Pathol; 2007;2:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case.
  • We present the case of a 39-year-old male with a tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty to enlarge a post-chemoradiation-induced shrunken bladder.
  • Cystoscopy revealed a papillary tumor at the site of ileovesical anastomosis, and transurethral resection was performed.
  • Histologic examination revealed a tubular adenoma with high-grade dysplasia.
  • There are only two previous reports of tubulovillous adenoma in ileal segment after ileocystoplasty, both without high-grade dysplasia.
  • Our observation supports the hypothesis that an ileal neobladder may undergo all the morphologic and molecular changes observed in the development of gastrointestinal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):84-8 [11743281.001]
  • [Cites] BJU Int. 2001 Aug;88(3):187-91 [11488727.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(3):202-4 [12775277.001]
  • [Cites] Int J Urol. 2003 Sep;10(9):495-7 [12941129.001]
  • [Cites] J Clin Pathol. 1992 Oct;45(10):928-9 [1430267.001]
  • [Cites] World J Urol. 2004 Sep;22(3):227-34 [15316739.001]
  • [Cites] J Urol. 1992 Apr;147(4):1013-6 [1552576.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1134-5 [16903947.001]
  • [Cites] Urology. 2006 Dec;68(6):1343.e9-10 [17141834.001]
  • [Cites] J Urol. 1991 Sep;146(3):862-6 [1714971.001]
  • [Cites] Urol Int. 1991;46(1):22-6 [2024366.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] J Urol. 1990 Sep;144(3):607-10 [2201791.001]
  • [Cites] J Urol. 1990 Nov;144(5):1110-4 [2231881.001]
  • [Cites] Br J Urol. 1989 Nov;64(5):489-92 [2611620.001]
  • [Cites] J Urol. 1989 Jan;141(1):178-81 [2908946.001]
  • [Cites] Urol Clin North Am. 1986 May;13(2):201-5 [3515722.001]
  • [Cites] J Urol. 1984 Dec;132(6):1108-11 [6502797.001]
  • [Cites] Science. 1980 Mar 7;207(4435):1079-80 [7355272.001]
  • [Cites] Urol Res. 1995;23(1):21-5 [7618231.001]
  • [Cites] J Urol. 1997 Feb;157(2):482-5; discussion 485-6 [8996339.001]
  • [Cites] Urol Clin North Am. 1997 Nov;24(4):723-8 [9391525.001]
  • [Cites] Br J Urol. 1998 Jan;81(1):55-61 [9467477.001]
  • [Cites] J Urol. 1998 Aug;160(2):490-1 [9679906.001]
  • [Cites] Eur Urol. 1999 Feb;35(2):98-101 [9933802.001]
  • [Cites] Eur Urol. 1999 Dec;36(6):588-94 [10559613.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1632-8 [10613486.001]
  • [Cites] Urology. 1999 Sep;54(3):561 [10754137.001]
  • [Cites] Urol Int. 2000;64(1):31-2 [10782030.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(1):CD003306 [12535469.001]
  • (PMID = 17697327.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1995190
  •  go-up   go-down


75. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F, PAPY Study Investigators: Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens; 2007 Jul;25(7):1433-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma.
  • The area under the receiver-operator characteristic curves (AUC) of aldosterone values after SIT was used as a measure of accuracy for diagnosing PA, aldosterone-producing adenoma (APA) or idiopathic hyperaldosteronism (IHA).
  • However, even at these optimal cut-offs, sensitivity and specificity were moderate because of values overlapping between patients with and without the disease.
  • [MeSH-major] Adenoma / blood. Adrenal Gland Neoplasms / blood. Aldosterone / blood. Hyperaldosteronism / diagnosis. Sodium Chloride

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563566.001).
  • [ISSN] 0263-6352
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride; 4964P6T9RB / Aldosterone; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


76. Orita Y, Hamaya K, Miki K, Sugaya A, Hirai M, Nakai K, Nose S, Yoshino T: Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland. Eur Arch Otorhinolaryngol; 2010 May;267(5):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland.
  • The occasional local recurrence of benign pleomorphic adenoma (PA) has generally been attributed to the vulnerability of the tumor capsule.
  • A total of 108 specimens of primary parotid gland PA resected at the Okayama Saiseikai General Hospital from 1988 to 2008 were microscopically reviewed.
  • Four (3.7%) patients displayed a main mass with satellite tumors in a single parotid gland.
  • In most cases, such satellite tumors will arise from capsular perforation of the primary tumor cells.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Neoplasms, Second Primary / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genes, p53 / genetics. Humans. Immunohistochemistry. Infant. Infant, Newborn. Ki-67 Antigen / genetics. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Point Mutation / genetics. Preoperative Care

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 1997 May;26(5):217-23 [9178173.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2003 Jun;28(3):262-6 [12755769.001]
  • [Cites] Br J Surg. 1958 Mar 18;45(193):477-87 [13536351.001]
  • [Cites] Acta Otolaryngol. 2007 Nov;127(11):1207-13 [17851915.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] Laryngoscope. 2001 Dec;111(12):2195-200 [11802025.001]
  • [Cites] J Laryngol Otol. 1977 Jul;91(7):629-32 [197179.001]
  • [Cites] J Laryngol Otol. 1976 Mar;90(3):295-8 [176288.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Nov;112(11):1180-4 [3019368.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):477-83 [10675478.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):531-4 [15308250.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 May;89(5):613-7 [10807720.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):455-7 [10699827.001]
  • [Cites] Laryngoscope. 1984 Mar;94(3):324-9 [6321863.001]
  • [Cites] Am J Surg. 1977 Aug;134(2):242-3 [196513.001]
  • [Cites] Ear Nose Throat J. 2002 May;81(5):341-5 [12025006.001]
  • [Cites] J Oral Pathol Med. 2008 May;37(5):309-18 [18248354.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1035-7 [6315839.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):594-6 [2547497.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1610-3 [14583757.001]
  • [Cites] Cancer Lett. 1992 Jul 31;65(1):61-71 [1324786.001]
  • [Cites] Head Neck. 2007 Aug;29(8):751-7 [17252593.001]
  • [Cites] Hum Pathol. 1996 Aug;27(8):782-6 [8760010.001]
  • [Cites] Acta Otolaryngol Suppl. 1964;188:SUPPL 191:1-99 [14156485.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2037-44 [7697591.001]
  • [Cites] Laryngoscope. 1982 Nov;92 (11):1265-8 [6292599.001]
  • [Cites] Histopathology. 2002 Dec;41(6):559-61 [12460210.001]
  • [Cites] Am J Surg. 1975 Oct;130(4):460-2 [1166937.001]
  • [Cites] Am J Surg. 1969 Nov;118(5):787-9 [4310431.001]
  • [Cites] Hum Pathol. 1995 Feb;26(2):135-8 [7860042.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Mar;87(3):341-5 [10102597.001]
  • (PMID = 19898859.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


77. Oliveira MA, Maeda SS, Dreyer P, Lobo A, Andrade VP, Hoff AO, Biscolla RP, Smanio P, Brandão CM, Vieira JG: [Importance of parathyroid SPECT and 99mTc scintigraphy, and of clinical, laboratorial, ultrasonographic and citologic correlation in the pre-operative localization of the parathyroid adenoma - pictorial assay]. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):352-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of parathyroid SPECT and 99mTc scintigraphy, and of clinical, laboratorial, ultrasonographic and citologic correlation in the pre-operative localization of the parathyroid adenoma - pictorial assay].
  • [Transliterated title] Importância da complementação com SPECT e 99mTc na cintilografia das paratiroides e da correlação clínica, laboratorial, ultrassonográfica e citológica na localização pré-operatória do adenoma de paratiroide - ensaio pictórico.
  • [MeSH-major] Adenoma / pathology. Adenoma / radionuclide imaging. Parathyroid Neoplasms / pathology. Parathyroid Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Bras Endocrinol Metabol. 2010 Jun;54(4):343-4 [20625644.001]
  • (PMID = 20625646.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


78. Schalin-Jäntti C: [Adrenal incidentaloma--a common dilemma]. Duodecim; 2010;126(9):1037-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An adrenal incidentaloma is an adrenal tumor larger than 1 cm, incidentally detected in imaging studies carried out for other reasons than adrenal disease.
  • The most frequent explanation is a benign, non-functional adenoma, other frequent diagnoses include cortisol- or aldosterone-secreting adenomas, pheochromocytoma, cortical carcinoma and metastatic lesions.
  • It is recommended to operate nonfunctional incidentalomas greater than 4 cm and follow-up smaller nonfunctional adenomas with a repeat CT.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Aldosterone / secretion. Humans. Hydrocortisone / secretion. Incidental Findings. Phenotype. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593627.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 21
  •  go-up   go-down


79. Jung MK, Jeon SW, Park SY, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH, Bae HI: Endoscopic characteristics of gastric adenomas suggesting carcinomatous transformation. Surg Endosc; 2008 Dec;22(12):2705-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic characteristics of gastric adenomas suggesting carcinomatous transformation.
  • BACKGROUND: Currently, endoscopic resections, including endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), are widely performed for the management of gastric neoplasia.
  • Gastric adenoma was diagnosed initially for all the patients.
  • These variables were analyzed and compared between an adenoma group (51 cases) and a carcinoma group (63 cases) on the basis of postresection diagnosis.
  • The diameter of the lesions was 14.6 +/- 8.2 mm in the adenoma group and 15.4 +/- 7.4 mm in the carcinoma group.
  • Characteristics of gastric adenomas such as a depressed type, red color, and ulceration that may have foci of carcinomas in other parts of the adenomas also should be considered for endoscopic resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Cell Transformation, Neoplastic / pathology. Gastroscopy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Disease Progression. Dissection / methods. Female. Gastric Mucosa / pathology. Humans. Male. Middle Aged. Risk Factors. Stomach Ulcer / etiology. Stomach Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 Oct;38(10):991-5 [17058163.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] Cancer. 1965 Jun;18:721-6 [14297468.001]
  • [Cites] Endoscopy. 2004 May;36(5):390-6 [15100945.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Cancer. 1990 May 1;65(9):2078-85 [2372773.001]
  • [Cites] Surg Clin North Am. 1989 Dec;69(6):1205-25 [2688151.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1001-6 [17058165.001]
  • [Cites] Surgery. 1956 Jan;39(1):114-9 [13298958.001]
  • [Cites] Cancer. 1971 Jun;27(6):1346-55 [5088211.001]
  • [Cites] Scand J Gastroenterol Suppl. 1990;178:7-12 [2277971.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4029-32 [16810753.001]
  • [Cites] Semin Surg Oncol. 1994 Mar-Apr;10 (2):100-6 [8052776.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Mar;22(3):311-4 [17295759.001]
  • [Cites] Hepatogastroenterology. 1998 Mar-Apr;45(20):579-82 [9638455.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S71-3 [16013003.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1016-25 [3661508.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):987-90 [17058162.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):114-8 [16330950.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Curr Top Pathol. 1976;63:77-93 [795617.001]
  • [Cites] Endoscopy. 1993 May;25(4):261-4 [8330542.001]
  • [Cites] Gut. 2002 Apr;50(4):465-70 [11889063.001]
  • [Cites] J Clin Pathol. 1985 Jul;38(7):754-64 [4019798.001]
  • [Cites] Scand J Gastroenterol. 2006 Sep;41(9):1105-9 [16938725.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1288-96 [7926493.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):501-6 [11437043.001]
  • [Cites] J Gastroenterol. 2006 Apr;41(4):397-8 [16741625.001]
  • [Cites] Scand J Gastroenterol Suppl. 1979;54:104-5 [295493.001]
  • [Cites] Semin Diagn Pathol. 2002 Feb;19(1):20-30 [11936263.001]
  • [Cites] Endoscopy. 1978 Feb;10(1):63-5 [631098.001]
  • [Cites] Endoscopy. 1993 May;25(4):265-8 [8330543.001]
  • [Cites] Endoscopy. 1994 Oct;26(8):659-65 [7859674.001]
  • [Cites] Minerva Med. 1972 Oct 27;63(76):4145-7 [4634553.001]
  • [Cites] Intern Med. 2005 Feb;44(2):85-6 [15750264.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):929-42 [17096062.001]
  • [Cites] Rev Gastroenterol Peru. 2005 Jan-Mar;25(1):76-92 [15818423.001]
  • [Cites] Intern Med. 2005 Oct;44(10):1033-8 [16293912.001]
  • [Cites] Endoscopy. 2003 Feb;35(2):118-26 [12561005.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2496-503 [7139542.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):119-21 [16045601.001]
  • [Cites] Lancet. 1997 Jun 14;349(9067):1725-9 [9193382.001]
  • (PMID = 18401651.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Al-Mefty O, Pravdenkova S, Gragnaniello C: A technical note on endonasal combined microscopic endoscopic with free head navigation technique of removal of pituitary adenomas. Neurosurg Rev; 2010 Apr;33(2):243-8; discussion 248-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A technical note on endonasal combined microscopic endoscopic with free head navigation technique of removal of pituitary adenomas.
  • The transsphenoidal approach is the approach of choice to treat most pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Microscopy. Nasal Cavity / surgery. Neuroendoscopy / methods. Neuronavigation. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2008 Oct;63(4 Suppl 2):244-56; discussion 256 [18981830.001]
  • [Cites] Neurosurgery. 1990 Jul;27(1):60-8 [2377282.001]
  • [Cites] Minim Invasive Neurosurg. 2008 Oct;51(5):272-4 [18855291.001]
  • [Cites] J Neurosurg. 1977 Mar;46(3):398-400 [839267.001]
  • [Cites] Union Med Can. 1962 Sep;91:933-45 [13952789.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Laryngoscope. 2007 Apr;117(4):699-705 [17334263.001]
  • [Cites] Acta Neurochir (Wien). 1978;41(1-3):163-75 [665329.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):237-56 [15527094.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):93-107 [12690982.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):140-2 [3783248.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):951-3 [1495359.001]
  • [Cites] J Neurooncol. 2008 May;87(3):317-25 [18094936.001]
  • [Cites] Ann Radiol (Paris). 1963;6:187-92 [13963490.001]
  • [Cites] Skull Base. 2002 Aug;12(3):119-24 [17167663.001]
  • [Cites] Pituitary. 1999 Aug;2(2):139-54 [11081165.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):435-42; discussion 442-4 [12182782.001]
  • [Cites] Neurosurg Focus. 2005 Dec 15;19(6):E2 [16398479.001]
  • [Cites] Neurosurgery. 1997 May;40(5):944-6 [9149252.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):161-9 [12182414.001]
  • [Cites] J Neurosurg. 2006 Mar;104(3):419-25 [16572655.001]
  • [Cites] Neurosurg Clin N Am. 2004 Jan;15(1):89-103 [15062407.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):661-70 [10405694.001]
  • [Cites] J Neurosurg. 2001 Dec;95(6):1083-96 [11765830.001]
  • (PMID = 20195677.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Müssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S: Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes; 2007 Mar;115(3):198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
  • BACKGROUND: Gigantism is rare with the majority of cases caused by a growth hormone (GH)-secreting pituitary adenoma.
  • Treatment options for GH-secreting pituitary adenomas have been widened with the availability of long-acting dopamine agonists, depot preparations of somatostatin analogues, and recently the GH receptor antagonist pegvisomant.
  • CASE REPORT: A 23-year-old male patient presented with continuous increase in height during the past 6 years due to a GH-secreting giant pituitary adenoma.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Gigantism / drug therapy. Gigantism / etiology. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery


82. Fracchia M, Senore C, Armaroli P, Ferraris R, Placido RD, Musso A, Turco D, Bellisario C, Baldi I, Segnan N: Assessment of the multiple components of the variability in the adenoma detection rate in sigmoidoscopy screening, and lessons for training. Endoscopy; 2010 Jun;42(6):448-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the multiple components of the variability in the adenoma detection rate in sigmoidoscopy screening, and lessons for training.
  • BACKGROUND AND STUDY AIMS: The determinants of the observed variability of adenoma detection rate (ADR) in endoscopy screening have not yet been fully explained.
  • To study the determinants of the ADR for distal adenomas, accounting for patient, examiner, and hospital characteristics, we applied a multivariate multilevel regression model.
  • RESULTS: Average ADRs for all adenomas and for advanced adenomas (size > or = 10 mm, villous component > 20 %, high grade dysplasia) were 13.5 % (range 5.2 %-25.0 %) and 6.4 % (3.1 %-10.7 %) for men, and 8.0 % (2.5 %-14.0 %) and 3.7 % (0.2 % - 7.4 %) for women.
  • In multivariate analysis, increased ADR of advanced adenomas was associated with male gender (odds ratio [OR] 1.78, 95 %CI 1.49 - 2.11), self-report of one first-degree relative with colorectal cancer (CRC) (1.44, 1.11-1.86), or of recent-onset rectal bleeding (1.73, 1.24-2.40).
  • Variability among pathologists in adenoma classification might explain part of the residual variability across endoscopy units.
  • [MeSH-major] Adenoma / diagnosis. Sigmoidoscopy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20414864.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


83. Wu Z, Ni D, Yan Y, Li J, Wang B, Ouyang J, Zhang G, Ma X, Li H, Zhang X: Expression of angiotensin II receptors in aldosterone-producing adenoma of the adrenal gland and their clinical significance. J Huazhong Univ Sci Technolog Med Sci; 2010 Aug;30(4):486-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiotensin II receptors in aldosterone-producing adenoma of the adrenal gland and their clinical significance.
  • The expression of angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R) in aldosterone-producing adenoma (APA) of the adrenal gland was detected, and their relationship with clinical indexes of APA was analyzed.
  • The expression of AT1R in adenoma, tissues adjacent to tumor, and normal tissues of the adrenal gland showed no significant differences.
  • The expression of AT2R in APA tissue was lower than that in normal adrenal gland tissues (P<0.05).
  • [MeSH-major] Adenoma / metabolism. Adrenal Gland Neoplasms / metabolism. Aldosterone / blood. Receptor, Angiotensin, Type 1 / metabolism. Receptor, Angiotensin, Type 2 / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 1995 Jan;60(1):28-34 [7792812.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1305-17 [12379765.001]
  • [Cites] J Steroid Biochem. 1979 Jul;11(1C):1043-50 [491637.001]
  • [Cites] Endocr Rev. 1998 Apr;19(2):101-43 [9570034.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):627-32 [11380493.001]
  • [Cites] J Am Coll Cardiol. 2005 Apr 19;45(8):1243-8 [15837256.001]
  • [Cites] J Clin Invest. 1991 Sep;88(3):921-33 [1885777.001]
  • [Cites] Lancet. 1999 Apr 17;353(9161):1341-7 [10218547.001]
  • [Cites] Folia Histochem Cytobiol. 2008;46(1):51-5 [18296263.001]
  • [Cites] Pharmacol Rev. 2000 Sep;52(3):415-72 [10977869.001]
  • [Cites] J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S57-61 [9892141.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):E303-9 [9950790.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):77-80 [7606933.001]
  • [Cites] Brain Res Bull. 1995;38(5):441-6 [8665267.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):19022-6 [9228085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10663-7 [7479861.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Sep;125(3):319-30 [1950344.001]
  • [Cites] Hypertension. 2000 Jan;35(1 Pt 2):155-63 [10642292.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):865-9 [9062498.001]
  • (PMID = 20714875.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AGTR1 protein, human; 0 / RNA, Messenger; 0 / Receptor, Angiotensin, Type 1; 0 / Receptor, Angiotensin, Type 2; 4964P6T9RB / Aldosterone
  •  go-up   go-down


84. Yu XY, Kong CZ, Li ZH, Sun ZX, Li ZL, Bi JB, Gong DX: [Study on multiple aldosterone-producing adenomas]. Zhonghua Wai Ke Za Zhi; 2007 Dec 15;45(24):1701-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on multiple aldosterone-producing adenomas].
  • OBJECTIVE: To investigate the experience on diagnosis and treatment of multiple adrenal aldosterone-producing adenomas (APA).
  • RESULTS: Adrenalectomy was performed for 4 cases of unilateral synchronous multiple APA, which were discovered with three adenomas by 3D-CT; bilateral tumor resection was performed for 6 cases of bilateral synchronous multiple APA.
  • There were 8 cases of bilateral metachronous multiple APA, including 2 cases of ipsilateral recurrent adrenal APA after adrenal tumor removal, which underwent tumor resection.
  • Another 6 cases were contralateral APA following adrenalectomy due to adrenal APA, and underwent tumor resection.
  • Tumor resection should be performed for bilateral or asynchronous APA, and it is very important to preserve healthy adrenal tissue as much as possible.
  • [MeSH-major] Adenoma / surgery. Adrenal Gland Neoplasms / surgery. Aldosterone / blood

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476531.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone
  •  go-up   go-down


85. Wang H, Li WS, Shi DJ, Ye ZP, Tai F, He HY, Liang CF, Gong J, Guo Y: Correlation of MMP(1) and TIMP (1) expression with pituitary adenoma fibrosis. J Neurooncol; 2008 Nov;90(2):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of MMP(1) and TIMP (1) expression with pituitary adenoma fibrosis.
  • OBJECTIVE: To explore the correlation of matrix metalloproteinase-1 (MMP(1)) and tissue inhibitor of metalloproteinase-1 (TIMP(1)) with pituitary adenoma fibrosis.
  • METHODS: Thirty-eight pituitary adenoma specimens were divided into fibrous group (6 patients) and non-fibrous group (32 patients).
  • CONCLUSION: The pathological features of pituitary adenoma fibrosis are excessive collagen deposition.
  • [MeSH-major] Adenoma / metabolism. Matrix Metalloproteinase 1 / metabolism. Pituitary Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Med Chir (Tokyo). 2002 May;42(5):202-12; discussion 213 [12064154.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2004 Jul;2(4):274-7 [15339415.001]
  • [Cites] Neurosci Bull. 2008 Feb;24(1):34-8 [18273074.001]
  • [Cites] Pathophysiology. 2004 Dec;11(3):153-158 [15561512.001]
  • [Cites] Ai Zheng. 2002 Jun;21(6):675-7 [12452074.001]
  • [Cites] Kidney Int. 2000 Sep;58(3):1186-201 [10972681.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 2):R1960-5 [9227614.001]
  • [Cites] Ann Trop Med Parasitol. 2004 Sep;98(6):581-93 [15324465.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2004 Nov;12(11):666-8 [15623375.001]
  • [Cites] Nihon Rinsho. 1993 Feb;51(2):428-34 [8464157.001]
  • [Cites] Histochem J. 1979 Jul;11(4):447-55 [91593.001]
  • [Cites] Exp Biol Med (Maywood). 2002 May;227(5):301-14 [11976400.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):779-86 [9810444.001]
  • [Cites] J Hand Surg Am. 2007 Mar;32(3):343-51 [17336841.001]
  • [Cites] Acta Gastroenterol Belg. 2000 Oct-Dec;63(4):366-70 [11233519.001]
  • [Cites] Immunology. 2004 Mar;111(3):343-52 [15009436.001]
  • [Cites] Beijing Da Xue Xue Bao. 2008 Feb 18;40(1):101-4 [18278151.001]
  • [Cites] Biotech Histochem. 2002 Mar;77(2):81-3 [12083388.001]
  • (PMID = 18604474.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 9007-34-5 / Collagen; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


86. Donangelo I, Araújo PB, Antenuzi D, Farage M, Marcondes J, Filho PN, Gadelha MR: Tumor deletion mapping of chromosomal region 13q14 in 43 growth hormone secreting pituitary adenomas. Endocrine; 2005 Nov;28(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor deletion mapping of chromosomal region 13q14 in 43 growth hormone secreting pituitary adenomas.
  • We performed a tumor deletion map of chromosomal region 13q14 with pituitary adenomas and matched blood samples of 43 patients with acromegaly.
  • Retention of marker D13S1325, telomeric to RB1, suggests that the putative tumor suppressor gene is located centromeric to this region, which includes RB1 locus.
  • Allelic loss occurred in similar frequency in invasive and noninvasive adenomas.
  • In summary, we confirmed the participation of chromosomal region 13q14 in a subset of GH-secreting adenomas with no regard to tumor grade.
  • RB1 was not implicated, suggesting the participation of another tumor suppressor gene in this region during the first steps of somatotropinoma development.
  • [MeSH-major] Adenoma / genetics. Chromosomes, Human, Pair 13 / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics
  • [MeSH-minor] Acromegaly / genetics. Chromosome Mapping. Human Growth Hormone / secretion. Humans. Loss of Heterozygosity. Neoplasm Invasiveness

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] Pituitary. 2003 Sep;6(2):75-80 [14703016.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7942-9 [12970742.001]
  • [Cites] Endocr Pathol. 2005 Spring;16(1):53-62 [16000847.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Eur J Endocrinol. 1999 Jun;140(6):573-6 [10366412.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1386-93 [8339229.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1388-91 [9543172.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):387-92 [8106627.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):401-7 [9033255.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1021-7 [8134105.001]
  • [Cites] FEBS Lett. 1998 Apr 17;426(2):266-70 [9599022.001]
  • [Cites] J Endocrinol Invest. 2000 May;23(5):304-9 [10882148.001]
  • [Cites] J Pediatr Endocrinol Metab. 1999 May-Jun;12(3):381-7 [10821217.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):44-50 [10389976.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5446-51 [9407947.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2631-4 [9709923.001]
  • [Cites] Eur J Endocrinol. 1996 Jun;134(6):720-6 [8766942.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1562-6 [10197629.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):250-5 [10216521.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1613-6 [7712461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3916-21 [10097138.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2815-21 [8514889.001]
  • [Cites] Oncol Res. 2001;12(11-12):491-500 [11939413.001]
  • [Cites] Science. 1990 Aug 10;249(4969):655-9 [2116665.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] J Pathol. 1999 Jun;188(2):168-73 [10398160.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):509-19 [9250163.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1421-6 [1977758.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):818-24 [9062489.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3210-2 [9745428.001]
  • [Cites] Microsc Res Tech. 2002 Oct 1;59(1):68-83 [12242698.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):141-50 [12580928.001]
  • [Cites] Semin Cancer Biol. 2000 Aug;10(4):255-69 [10966849.001]
  • [Cites] Cell. 2001 Dec 28;107(7):823-6 [11779458.001]
  • [Cites] Endocr J. 2003 Jun;50(3):309-18 [12940460.001]
  • [Cites] Cancer Lett. 1999 Sep 20;144(1):85-92 [10503881.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Oct;129(4):301-6 [8237246.001]
  • (PMID = 16388084.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


87. Martins AM, Vasques-Peyser A, Torres LN, Matera JM, Dagli ML, Guerra JL: Retrospective--systematic study and quantitative analysis of cellular proliferation and apoptosis in normal, hyperplastic and neoplastic perianal glands in dogs. Vet Comp Oncol; 2008 Jun;6(2):71-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aetiology is unknown, and most of them are benign.
  • Nine cases (4%) were diagnosed as hyperplasia, 49 (20%) as group I adenoma, 81 (34%) were classified as moderately differentiated adenomas of the group II, 46 (19%) were poorly differentiated adenomas of group II, 48 (20%) were carcinoma of the group III according to the classification proposed by Berrocal, and 7 (13%) were other kind of tumours.
  • Cell proliferation was quantified by counting proliferating cell nuclear antigen (PCNA) positive nuclei, and apoptosis was quantified by counting fluorescent eosin-stained apoptotic corpuscles (AC) in normal tissue, hyperplasia and in different histologic types of neoplasia of these glands.
  • NGI was different between hyperplasia and neoplasia; group I adenomas have a much higher potential of growth, and NGI decreases from benign towards malignant lesions.
  • These results show up the importance of studying cell proliferation and apoptosis to understand the carcinogenesis of dog perianal gland.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Apoptosis. Dog Diseases / pathology. Hyperplasia / veterinary. Perianal Glands / cytology. Proliferating Cell Nuclear Antigen / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178666.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


88. Koulouris G, Pianta M, Stuckey S: The 'sentinel clot' sign in spontaneous retropharyngeal hematoma secondary to parathyroid apoplexy. Ear Nose Throat J; 2006 Sep;85(9):606-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spontaneous retropharyngeal hemorrhage from a cervical parathyroid adenoma is a rare complication of primary hyperparathyroidism.
  • Awareness of a possible thyroid or parathyroid etiology may expedite treatment and prevent unnecessary interventions.
  • [MeSH-major] Adenoma / complications. Hematoma / etiology. Parathyroid Neoplasms / complications. Retroperitoneal Space

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044430.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Nguyen HD, Galitz MS, Mai VQ, Clyde PW, Glister BC, Shakir MK: Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. Thyroid; 2010 Jan;20(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
  • BACKGROUND: A thyrotropin (TSH)-secreting pituitary adenoma coexisting with differentiated thyroid carcinoma is rare.
  • She has remained asymptomatic for 24 months without biochemical or radiological evidence of pituitary hormone oversecretion, pituitary adenoma enlargement, and PTC recurrence.
  • CONCLUSION: To our knowledge, this is the first case of a TSH/growth-hormone-secreting pituitary macroadenoma coexisting with PTC being successfully treated with octreotide and levothyroxine after thyroidectomy and recombinant human TSH-stimulated radioactive iodine remnant ablation.
  • [MeSH-major] Adenoma. Carcinoma, Papillary. Human Growth Hormone / biosynthesis. Neoplasms, Multiple Primary. Pituitary Neoplasms. Thyroid Neoplasms. Thyrotropin / biosynthesis

  • Genetic Alliance. consumer health - Pituitary adenoma, growth hormone-secreting.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067380.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


90. Steward DL, Danielson GP, Afman CE, Welge JA: Parathyroid adenoma localization: surgeon-performed ultrasound versus sestamibi. Laryngoscope; 2006 Aug;116(8):1380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid adenoma localization: surgeon-performed ultrasound versus sestamibi.
  • OBJECTIVES: Compare surgeon-performed ultrasound versus sestamibi for preoperative parathyroid adenoma localization.
  • Primary outcome is sensitivity for adenoma localization to correct quadrant (right vs. left, superior vs. inferior).
  • [MeSH-major] Adenoma / diagnosis. Parathyroid Neoplasms / diagnosis. Technetium Tc 99m Sestamibi

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laryngoscope. 2007 Feb;117(2):382; author reply 382-3 [17277637.001]
  • (PMID = 16885740.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


91. Tanaka Y, Shibata T, Suzuki K: Pleomorphic adenoma originating from the trachea showing the appearance of a follicular tumor of the thyroid on ultrasonography. J Med Ultrason (2001); 2010 Jan;37(1):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma originating from the trachea showing the appearance of a follicular tumor of the thyroid on ultrasonography.
  • Pleomorphic adenoma (PA) is the most common tumor of the salivary gland.
  • This report presents a case of a PA originating from the trachea that looked like a thyroid neoplasm on ultrasonography, showing a well-circumscribed, hypovascular, solid, and hypoechoic tumor within the thyroid.
  • The tumor was resected with the right lobe of the thyroid and the first tracheal ring, which revealed a PA impacted within the thyroid.
  • This report describes the first reported, and unique, case of this type of tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ear Nose Throat J. 2008 May;87(5):288-90 [18572787.001]
  • [Cites] J Med Case Rep. 2008 Nov 17;2:349 [19014678.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2008 Mar 01;13(3):E193-6 [18305442.001]
  • [Cites] Surg Today. 2007;37(6):493-5 [17522768.001]
  • [Cites] Pathol Res Pract. 2008;204(4):273-6 [18295980.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2008 Jan 01;13(1):E58-60 [18167483.001]
  • [Cites] Yonsei Med J. 1996 Feb;37(1):81-5 [8967114.001]
  • [Cites] Med J Malaysia. 2007 Jun;62(2):162-3 [18705454.001]
  • [Cites] Histopathology. 2007 Dec;51(6):868-71 [17916072.001]
  • (PMID = 27277607.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Follicular tumor of the thyroid / Pleomorphic adenoma / Tracheal tumor
  •  go-up   go-down


92. Ide F, Kikuchi K, Kusama K, Kanazawa H: Sialadenoma papilliferum with potentially malignant features. J Clin Pathol; 2010 Apr;63(4):362-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sialadenoma papilliferum (SP) is a benign non-invasive lesion with slow and limited growth.
  • Histological features were also atypical: surface verrucous hyperplasia and deeper florid cystic-duct adenoma.
  • [MeSH-major] Adenoma / diagnosis. Mandibular Neoplasms / diagnosis. Papilloma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354209.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Dopamine agonist: pathological gambling and hypersexuality. Prescrire Int; 2008 Oct;17(97):200-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) Most affected patients are being treated for Parkinson's disease, but cases have been reported among patients prescribed a dopamine agonist for restless legs syndrome or pituitary adenoma;.
  • [MeSH-minor] Australia. Canada. Crime. Drug Overdose. Europe. Female. Humans. Male. Parkinson Disease / drug therapy. Pituitary Neoplasms / drug therapy. Restless Legs Syndrome / drug therapy. Risk-Taking. Sex Offenses. Theft

  • MedlinePlus Health Information. consumer health - Compulsive Gambling.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536937.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dopamine Agents; 0 / Dopamine Agonists
  •  go-up   go-down


94. Winczyk K: [The role of peroxisome proliferators-activated receptors (PPARgamma) in neoplasms of endocrine glands]. Endokrynol Pol; 2008 Mar-Apr;59(2):156-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of PPARgamma was detected in normal and tumor cells of endocrine glands.
  • The reports about oncostatic effects of PPARgamma agonists in pituitary adenomas, thyroid cancers and adrenal tumor are reviewed.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic. PPAR gamma / metabolism. Pituitary Neoplasms / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18465691.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / PPAR gamma
  • [Number-of-references] 135
  •  go-up   go-down


95. Pérez-Núñez A, Miranda P, Arrese I, González P, Ramos A, Lobato RD: Lymphocytic hypophysitis with cystic MRI appearance. Acta Neurochir (Wien); 2005 Dec;147(12):1297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphocytic hypophysitis (LH) is an infrequent primary inflammatory disorder, which is usually diagnosed after surgery for lesions suspected to be pituitary adenomas.
  • Some radiological features have been described that may allow a preoperative diagnosis, such as a symmetric enlargement of the gland with diffuse contrast enhancement extending to the basal hypothalamus in a tongue-like fashion.
  • We describe the case of a patient with LH presenting with the MR imaging of a cystic lesion with ring contrast enhancement.
  • It seems that this appearance in imaging studies is not unusual, and should be considered among the features suggesting this disease in an appropriate clinical context.
  • [MeSH-major] Cysts / diagnosis. Encephalitis / diagnosis. Pituitary Diseases / diagnosis. Pituitary Gland / pathology


96. Farris AB, Misdraji J, Srivastava A, Muzikansky A, Deshpande V, Lauwers GY, Mino-Kenudson M: Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol; 2008 Jan;32(1):30-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps.
  • Sessile serrated adenoma (SSA) is the proposed precursor for microsatellite unstable colorectal carcinomas and some authorities recommend that SSAs should be managed similar to adenomas.
  • One hundred eighty-five serrated polyps were classified as hyperplastic polyp (HP), SSA, or traditional serrated adenoma (TSA) by 5 pathologists blinded to clinical data.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Intestinal Polyps / pathology


97. Horvath E, Kovacs K: Pathology of acromegaly. Neuroendocrinology; 2006;83(3-4):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic, immunohistochemical and electron microscopic study provided conclusive evidence that a marked diversity exists between the tumors which secrete growth hormone (GH) in excess, such as densely and sparsely granulated GH cell adenoma, the mixed GH prolactin cell adenoma and the mammosomatotrope adenoma.
  • [MeSH-major] Acromegaly / pathology. Human Growth Hormone / metabolism. Pituitary Gland / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenoma / therapy. Adenoma / ultrastructure. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma / ultrastructure. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047379.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  • [Number-of-references] 22
  •  go-up   go-down


98. Hirai H, Shibata T, Sasaki Y, Fujii H, Kubo S, Suehiro S: Simultaneous surgery for chronic aortic dissection and adrenal adenoma with primary aldosteronism. Gen Thorac Cardiovasc Surg; 2010 May;58(5):235-7; discussion 238
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous surgery for chronic aortic dissection and adrenal adenoma with primary aldosteronism.
  • Magnetic resonance images showed a 1-cm nodule in the left adrenal gland.
  • Graft replacement for aortic dissection under extracorporeal circulation and resection of the left adrenal gland were undertaken simultaneously.
  • [MeSH-major] Adenoma / surgery. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Aneurysm, Dissecting / surgery. Aortic Aneurysm, Thoracic / surgery. Blood Vessel Prosthesis Implantation. Hyperaldosteronism / surgery. Hypertension / surgery
  • [MeSH-minor] Adult. Antihypertensive Agents / therapeutic use. Aortography / methods. Blood Pressure. Chronic Disease. Humans. Magnetic Resonance Imaging. Male. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Angiology. 1999 Jun;50(6):503-8 [10378827.001]
  • [Cites] Horm Res. 2009 Jan;71 Suppl 1:8-12 [19153497.001]
  • [Cites] Cardiology. 2007;108(1):48-50 [16988504.001]
  • [Cites] Curr Probl Cardiol. 2009 Feb;34(2):51-84 [19135616.001]
  • [Cites] Curr Vasc Pharmacol. 2009 Apr;7(2):244-49 [19356005.001]
  • [Cites] Clin Sci (Lond). 2007 Sep;113(6):267-78 [17683282.001]
  • (PMID = 20449714.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  •  go-up   go-down


99. Foppiani L, Del Monte P, Ruelle A, Bandelloni R, Quilici P, Bernasconi D: TSH-secreting adenomas: rare pituitary tumors with multifaceted clinical and biological features. J Endocrinol Invest; 2007 Jul-Aug;30(7):603-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSH-secreting adenomas: rare pituitary tumors with multifaceted clinical and biological features.
  • TSH-secreting pituitary adenomas (TSH-omas) are a rare cause of hyperthyroidism in clinical practice.
  • In the 2 patients who underwent neurosurgery, hormonal hypersecretion by the tumor normalized.
  • In one of these patient (case 1), however, the presence of a tumor remnant inside the left cavernous sinus prompted us, in accordance with the patient, to start therapy with octreotide- long-acting release.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Thyrotrophs / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Sep;54(2):179-86 [11761434.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):176-81 [15670193.001]
  • [Cites] Trends Endocrinol Metab. 1992 Mar;3(2):41-5 [18407076.001]
  • [Cites] South Med J. 2003 Sep;96(9):933-6 [14513996.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Eur J Nucl Med. 1997 Jul;24(7):728-31 [9211757.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1529-38 [11518802.001]
  • [Cites] Am J Med. 2005 Jul;118(7):706-14 [15989900.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3084-90 [8768879.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):735-43 [12072042.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):524-8; quiz following p528 [16957766.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5572-6 [11701737.001]
  • [Cites] Pituitary. 2002;5(2):83-8 [12675505.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):708-11 [14764785.001]
  • (PMID = 17848845.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


100. Kim DH, Kim SU, Nam DH, Choi YJ, Park SM, Lee CK, Kim DY: A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J Intern Med; 2009 Jun;24(2):147-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male.
  • Hepatocellular adenoma (HA) is a benign hepatic lesion that predominantly occurs in young women.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1983 May;84(5 Pt 1):994-1002 [6299876.001]
  • [Cites] JAMA. 1979 Aug 17;242(7):644-8 [221698.001]
  • [Cites] Arch Pathol Lab Med. 1987 Feb;111(2):166-9 [3545138.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):47-51 [9577372.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Apr;18(4):437-41 [16538118.001]
  • [Cites] Hepatogastroenterology. 2007 Mar;54(74):386-8 [17523280.001]
  • [Cites] Taehan Kan Hakhoe Chi. 2002 Mar;8(1):107-9 [12499824.001]
  • [Cites] J Formos Med Assoc. 2002 Nov;101(11):798-802 [12517062.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2379-81 [14562419.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1382-4 [11100357.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):877-92; discussion 892-4 [11452062.001]
  • [Cites] J Clin Pathol. 1973 Mar;26(3):217-23 [4700503.001]
  • [Cites] Lancet. 1973 Oct 27;2(7835):926-9 [4126557.001]
  • [Cites] N Engl J Med. 1976 Feb 26;294(9):470-2 [173996.001]
  • [Cites] Gastroenterology. 1977 Aug;73(2):386-94 [194813.001]
  • [Cites] Ann Intern Med. 1989 Mar 15;110(6):489-90 [2537593.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):558-64 [3190282.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):547-9 [3019201.001]
  • (PMID = 19543495.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 26
  • [Other-IDs] NLM/ PMC2698597
  • [Keywords] NOTNLM ; Adenoma / Hepatocellular / Hepatocellular carcinoma
  •  go-up   go-down






Advertisement